**SYSTEMATIC REVIEW AND META-ANALYSIS**

Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape

Laura E. Bruijn, BSc; Brendy E. W. M. van den Akker, BSc; Connie M. van Rhijn, BSc; Jaap F. Hamming, MD, PhD; Jan H. N. Lindeman, MD, PhD

**BACKGROUND:** Human mesenchymal cells are culprit factors in vascular (patho)physiology and are hallmarked by phenotypic and functional heterogeneity. At present, they are subdivided by classic umbrella terms, such as “fibroblasts,” “myofibroblasts,” “smooth muscle cells,” “fibrocytes,” “mesangial cells,” and “pericytes.” However, a discriminative marker-based subclassification has to date not been established.

**METHODS AND RESULTS:** As a first effort toward a classification scheme, a systematic literature search was performed to identify the most commonly used phenotypical and functional protein markers for characterizing and classifying vascular mesenchymal cell subpopulation(s). We next applied immunohistochemistry and immunofluorescence to inventory the expression pattern of identified markers on human aorta specimens representing early, intermediate, and end stages of human atherosclerotic disease. Included markers comprise markers for mesenchymal lineage (vimentin, FSP-1 [fibroblast-specific protein-1]/S100A4, cluster of differentiation (CD) 90/thymocyte differentiation antigen 1, and FAP [fibroblast activation protein]), contractile/non-contractile phenotype (α-smooth muscle actin, smooth muscle myosin heavy chain, and nonmuscle myosin heavy chain), and auxiliary contractile markers (h1-Calponin, h-Caldesmon, Desmin, SM22α [smooth muscle protein 22α], non-muscle myosin heavy chain, smooth muscle myosin heavy chain, Smoothelin-B, α-Tropomyosin, and Telokin) or adhesion proteins (Paxillin and Vinculin). Vimentin classified as the most inclusive lineage marker. Subset markers did not separate along classic lines of smooth muscle cell, myofibroblast, or fibroblast, but showed clear temporal and spatial diversity. Strong indications were found for presence of stem cells/Endothelial-to-Mesenchymal cell Transition and fibrocytes in specific aspects of the human atherosclerotic process.

**CONCLUSIONS:** This systematic evaluation shows a highly diverse and dynamic landscape for the human vascular mesenchymal cell population that is not captured by the classic nomenclature. Our observations stress the need for a consensus multiparameter subclass designation along the lines of the cluster of differentiation classification for leucocytes.

**Key Words:** atherosclerosis ■ fibroblasts ■ myofibroblasts ■ vascular smooth muscle cells

Vascular mesenchymal cells are critically involved in blood vessel development and homeostasis and are progressively acknowledged as key effector cells in vascular pathological conditions, such as atherosclerosis, aneurysmal disease, and neointima formation.

In the context of vascular pathology, mesenchymal cells are generally subclassified by classic umbrella terms, such as “fibroblasts,” “myofibroblasts,” “smooth muscle cells” (SMCs), “fibrocytes,” “mesangial cells,” and “pericytes.” This generic nomenclature is based on the process under investigation, their presumed function or specific anatomical location, and/or their in vitro behavior. At this point, a discriminative consensus (sub)classification for vascular mesenchymal cells, let alone classifying marker sets required for mechanistic understanding, is needingly missing. In this light, and in the context of the emerging key roles for mesenchymal cells in human vascular disease, we considered a systematic
To address this point, we performed a systematic literature search to identify candidate mesenchymal cell-specific markers, and evaluated the expression pattern and the expression dynamics of the identified markers in different stages of the human atherosclerotic process.

**Methods**

This study is based on a 2-step approach. First, we conducted a systematic literature search to map the reported markers for vascular mesenchymal cell subpopulation characterization and classification. Subsequently, we applied immunohistochemistry and immunofluorescence to evaluate the specificity and expression pattern of the identified markers in a representative sample of early, intermediate, and (stabilized) end stages of the human aortic atherosclerotic process (Virmani classification, respectively: adaptive intimal thickening [AIT], late fibroatheroma [LFA], and fibrocalcific plaque [FCP]) (Figure 1).

The authors declare that all supporting data are available within the article (and its online supplementary files).

**Systematic Literature Review of Phenotypical Immunohistochemical Markers**

A systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were identified by searching PubMed and Embase. The search strategy (outlined in Data S1 and S2 [Systematic Review Protocol]) was based on 3 search themes, combined in the search by AND. The first theme was created for vascular remodeling and phenotypic heterogeneity. The second theme included descriptions of fibroblasts, myofibroblasts, and SMCs. The final, third theme consisted of terms for atherosclerosis, aortic aneurysmal disease, and fibrosis. Because the focus of the study was on the classic supportive mesenchymal vascular cell type, we considered aspects of osteogenic, adipogenic, and pericyte differentiation beyond the scope of the literature review.

The search was most recently updated in December 2019. First, 2 authors (J.L. and L.B.) independently reviewed the titles and abstracts for eligibility. Thereafter, full-text articles were assessed.

In parallel to the above phenotypic markers, we mapped reported markers of a synthetic and proinflammatory phenotype for functional sub-classification, as these functions are considered independent of the cell phenotype (ie, SMCs, myofibroblasts, and fibroblasts can be synthetic and/or inflammatory).

**Human Atherosclerotic Tissue Sampling**

Formalin-fixed, paraffin-embedded aortic wall samples were selected from the Vascular Tissue Repository at the Department of Vascular Surgery, Leiden, the Netherlands. These human perirenal aortic patches were obtained during clinical organ transplantation.
with grafts derived from cadaveric donors. Histologic sections were prepared for each tissue block, sections were Movat pentachrome stained (for protocol, see Data S3), and the extent of atherosclerosis was classified (modified American Heart Association classification, according to Virmani et al\textsuperscript{10}) The tissue block showing the highest degree of atherosclerosis was used as the reference block. For this evaluation, we randomly selected preclassified tissue blocks representative for AIT, LFA, and FCP (Figure 1). All stainings were performed on sequential tissue sections from the selected tissue blocks.

To evaluate mesenchymal cell presence in respectively progressive and stabilizing atherosclerotic lesions, representative sections of the unstable lesion thin cap fibroatheroma\textsuperscript{10} in addition to the stable lesion LFA and healed rupture (HR)\textsuperscript{10} were selected. HR was selected as well because of a suspected enrichment of the mesenchymal cell subtype fibrocytes.\textsuperscript{11}

**Immunohistochemical Staining on Atherosclerotic Lesions**

**Single-Labeling Immunohistochemistry**

Consecutive (4-μm) sections were immunostained for the 28 immunohistochemistry markers (Table 1) identified in the literature review. All single stainings were performed by immunohistochemistry, because immunohistochemistry allows for direct clear overview, provides superior contextual information, and is not interfered by background staining (mainly caused by elastin) when assessed by immunofluorescence.
Heat-induced (Tris/EDTA, pH 9.2/citrate, pH 6) or enzyme-induced antigen retrieval was performed if required (Table 1).

All primary antibodies were diluted in 1% BSA/PBS and were incubated overnight at 4°C. Endogenous peroxidase activity was blocked with a 20-minute incubation of 0.3% hydrogen peroxide. The Envision/3,3’-diaminobenzidine (Dako, Glostrup, Denmark) system was used for visualization. Nuclei were counterstained by Mayer hematoxylin (Merck Millipore, Amsterdam, the Netherlands). Slides stained for phosphorylated nuclear factor-κB were washed with Triton X-100 (Abcam, Cambridge, UK) 0.1% in PBS for 10 minutes. All stainings for a given antibody were processed in a single batch.

Imaging of Immunohistochemistry Slides

Immunohistochemistry images were captured by means of a digital microscope (Philips IntelliSite Pathology Solution Ultra-Fast Scanner; Philips Eindhoven, the Netherlands).

Evaluation of Marker Expression on Atherosclerotic Tissue

For all markers, expression patterns were inventoried for 6 separate aspects of the aortic wall (see Figure S1 for an outline): intima, inner media, middle media, outer media, adventitia, as well as at the level of the arteriole-type (thick-walled) vasa vasorum and venule-type (thin-walled) vasa vasorum in the adventitia. In addition, we evaluated the mesenchymal populations in the areas adjacent to shoulders of and covering (multilayered fibrous cap) the necrotic core of the LFA-type lesion. For the FCP lesion type, the cells in the newly formed intima overlying the fibrous lesion, rather than the remnants of the former fibrous cap, were appreciated.

Scoring was performed by 2 observers using semiquantitative scoring estimates (ie, 0%, <10%, 10%–50%, or >50% positivity) for each region.

Multilabeling Immunohistochemistry

Double-labeling stainings were primarily performed by immunohistochemistry, for the same reasons single
immunohistochemistry stainings were preferred over single immunofluorescence stainings. Double-labeling immunohistochemistry stainings were performed by sequential single-labeling immunohistochemistry. A second heat-induced antigen retrieval after the first chromogen staining was used to inactivate the previous signal. All epitopes resisted the second heat retrieval. Vulcan red (10 minutes, dilution 1:50) and Ferangi blue (5 minutes, dilution 1:50; both from BioCare Medical, Pacheco, CA; both alkaline phosphatase enzymatic chromogens) were combined in the double staining because these chromogens provide optimal color separation and a clear colocalization signal (purple). Double-stained slides were not counterstained.

**Immunofluorescence Staining**

**Multilabeling Immunofluorescence**

Colocalization of >2 markers was visualized by immunofluorescence, as no triple chromogen panel could be established that provided adequate color differentiation.

All primary (Table 2) and Alexa Fluor secondary antibodies (dilution 1:200; Thermofisher, Waltham, MA) were diluted in 1% PBS/BSA and incubated overnight at 4°C and 60 minutes at room temperature, respectively. Negative controls were created by omitting the primary antibodies, and antigen stability was checked after the first heat retrieval.

In the triple-labeling immunofluorescence stainings, cluster of differentiation (CD) 45 staining was first performed as a single staining: the CD45 antibody was incubated overnight and visualized using goat anti-mouse (MACH2 AP-Polymer; Biocare Medical) as a secondary antibody (30 minutes incubation at room temperature) and visualized using Vulcan Fast Red (10 minutes, dilution 1:50; Biocare Medical) fluorescence. After a second heat retrieval, the other 2 antibodies of different isotypes were incubated overnight and corresponding fluorescent-labelled secondary antibodies were applied.

Slides were mounted using ProLong Gold with 4',6-diamidino-2-phenylindole antifade reagent (Thermofisher) and stored at 4°C until analysis. Vulcan
### Table 1. Antibodies Used for Immunohistochemistry

| Antibody, Clone or Catalog No. | Source                        | Secondary Antibody | Dilution | Protein Block (Dako) | Prettreatment | Cellular Localization | Purification | Protein Subclass | Host Isotype; Subclass Purification | Subcellular Localization | Source | Protein and Protein Processing | Pretreatment | Source | Source | Source |
|-------------------------------|-------------------------------|--------------------|----------|----------------------|---------------|-----------------------|--------------|------------------|-----------------------------------|--------------------------|---------|-----------------------------------|-------------------------|---------|---------|---------|
| Vimentin, I5G2a               | Mouse IgG2a                   |                   | 1:2000   | No                   |               | Cytoskeleton (intermediate filament) | Purified from cell culture supernatant |                |                     |                                   |                          |         |                     |                       |         |         |         |
| FSP-1 (1:50000)               | Rabbit IgG                   |                   | 1:1000   | No                   |               | Cytoskeleton (myosin filaments) | Purified from tissue culture supernatant |                |                     |                                   |                          |         |                     |                       |         |         |         |
| Thy-1 (1:2000)                | Rabbit IgG                   |                   | 1:1000   | No                   |               | Cytoskeleton (myosin filaments) | Purified from tissue culture supernatant |                |                     |                                   |                          |         |                     |                       |         |         |         |
| gSMI-38 (1:2000)              | Rabbit IgG                   |                   | 1:1000   | No                   |               | Cytoskeleton (myosin filaments) | Purified from tissue culture supernatant |                |                     |                                   |                          |         |                     |                       |         |         |         |
| SM-MHC (1:2000)               | Mouse IgG1                    |                   | 1:1000   | No                   |               | Cytoskeleton (microfilaments) and ECM | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |
| Cap (1:300)                   | Mouse IgG1                    |                   | 1:300    | No                   |               | Cytoskeleton (microfilaments) and ECM | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |
| Calponin, hCO                 | Mouse IgG1                    |                   | 1:300    | No                   |               | Cytoskeleton (thin filament-associated protein) | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |
| Des (1:2000)                  | Mouse IgG1                    |                   | 1:2000   | No                   |               | Cytoskeleton (microfilaments) and ECM | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |
| SM22a (1:2000)                | Mouse IgG1                    |                   | 1:2000   | No                   |               | Cytoskeleton (microfilaments) and ECM | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |
| Smoothelin, R4A               | Mouse IgG1                    |                   | 1:2000   | No                   |               | Cytoskeleton (intermediate filament) | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |
| Smooth muscle protein 220 kDa | Mouse IgG1                    |                   | 1:2000   | No                   |               | Cytoskeleton (intermediate filament) | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |
| Troponin, F-G                 | Mouse IgG2a                   |                   | 1:2000   | No                   |               | Cytoskeleton (intermediate filament) | Immunogen affinity purified |                |                     |                                   |                          |         |                     |                       |         |         |         |

*(Continued)*
| Antibody, Clone or Catalog No. | Abbreviation Used in Study | Host Isotype; Subclass | Purification | Cellular Localization | Pretreatment | Protein Block (Dako) | Dilution | Secondary Antibody | Source |
|-------------------------------|-----------------------------|------------------------|--------------|-----------------------|--------------|---------------------|---------|-------------------|--------|
| Myosin light chain kinase/ Telokin | Telokin | Rabbit IgG | Not specified | Cytoskeleton (myosin binding) | No retrieval | No | 1:1000 | DAKO EnVision+ System, anti-rabbit | Bosterbio |
| Paxillin, SH11 | Pax | Mouse IgG1 | Protein G | Cytoplasm > cytoskeleton (focal adhesion protein) | Tris-EDTA (pH 9.2) | No | 1:500 | DAKO EnVision+ System, anti-rabbit | Invitrogen |
| Vinculin, HVIN-1 | Vinc | Mouse IgG1 | Unpurified | Cytoskeleton (actin binding) | Citrate (pH 6) | No | 1:200 000 | DAKO EnVision+ System, anti-rabbit | Novusbio |
| Collagen-I, MB502155 | Coll-I | Rabbit IgG | Affinity chromatography | ECM | Citrate (pH 6), Tris-EDTA (pH 9.2), and pepsin | No | No specific signal | DAKO EnVision+ System, anti-rabbit | MyBioSource |
| Collagen-I, C7510-17K | Coll-I | Goat IgG | Affinity chromatography | ECM | Citrate (pH 6), Tris-EDTA (pH 9.2), and pepsin | No | No specific signal | Donkey anti-goat IgG-HRP, AB97120 (Abcam) | USBIO |
| Procollagen-I, PC8-7 | Procol-I | Mouse IgG1 | Not specified | Secreted | Citrate (pH 6) and Tris-EDTA (pH 9.2) | No | No specific signal | DAKO EnVision+ System, anti-mouse | Abnova |
| Procollagen-I, M58 | Procol-I | Rat IgG1 | Affinity chromatography | Secreted | Citrate (pH 6) and Tris-EDTA (pH 9.2) | No | No specific signal | Goat anti-rat IgG-Biotine, BA-9401 (Vector) | Chemicon International |
| Prolyl 4-hydroxylase β, 3-2B12 | Prolyl 4-HB | Mouse IgG1 | Affinity chromatography | Endoplasmic reticulum lumen, cell membrane | Citrate (pH 6) | No | 1:4000 | DAKO EnVision+ System, anti-mouse | Acris Antibodies |
| Osteopontin, AF1433 | OPN | Polyclonal goat IgG | Antigen affinity purified | ECM | Tris-EDTA (pH 9.2) | No | 1:100 | Donkey anti-goat IgG-HRP, AB97120 (Abcam) | R&D Systems |
| Fibronectin, FBN11 | FBN | Mouse IgG1 | Protein G | ECM | Tris-EDTA (pH 9.2) | No | 1:900 | DAKO EnVision+ System, anti-mouse | Thermofisher |
| Laminin, ab11575 | LAm | Polyclonal rabbit IgG | Immunogen affinity purified | ECM | Tris-EDTA (pH 9.2) | No | 1:200 | DAKO EnVision+ System, anti-rabbit | Abcam |
| Cellular retinoid-binding protein-I, B8 | CRBP-I | Mouse IgG1 | Not specified | Cytoplasm | Citrate (pH 6) and Tris-EDTA (pH 9.2) | No | No signal | DAKO EnVision+ System, anti-rabbit | Santa Cruz Biotechnology |
| Platelet-derived growth factor receptor α, ab61219 | PDGF-α | Rabbit IgG | Immunogen affinity purified | Cell membrane | Citrate (pH 6) and Tris-EDTA (pH 9.2) | No | A specific signal (nuclear) | DAKO EnVision+ System, anti-rabbit | Abcam |
| Phosphorylated nuclear factor-xB p65, 17B'3 | NF-κB | Rabbit IgG | Not specified | Nucleus | Citrate (pH 6), Tris-EDTA (pH 9.2), and pepsin | No | No specific signal | DAKO EnVision+ System, anti-rabbit | Cell Signaling Technology |
| Phosphorylated nuclear factor-xB p65, MCF-7A0 | NFκB | Mouse IgG1 | Antigen affinity purified | Nucleus | Citrate (pH 6), Tris-EDTA (pH 9.2), and pepsin | No | No specific signal | DAKO EnVision+ System, anti-mouse | eBioscience |
| Interleukin 6, NYRhIL6 | IL-6 | Mouse IgG2a | Not specified | Secreted | Citrate (pH 6) | Yes | 1:300 | DAKO EnVision+ System, anti-mouse | Santa Cruz Biotechnology |

(Continued)
### Table 1. Continued

| Antibody, Clone or Catalog No. | Abbreviation Used in Study | Host/Isotype, Subclass | Purification | Cellular Localization | Pretreatment | Protein Block (DAKO) | Dilution | Secondary Antibody Source | Source |
|--------------------------------|-----------------------------|------------------------|--------------|-----------------------|--------------|----------------------|----------|---------------------------|--------|
| Monocyte chemoattractant protein-I, 23002 | MCP-1 | Mouse IgG2b | Protein A or G | Secreted | Citrate (pH 6), Tris-EDTA (pH 9.2), and pepsin | No | No signal | DAKO EnVision+ System, anti-mouse | R&D Systems |
| Interleukin 8, bs0708R | IL-8 | Rabbit IgG | Protein A | Secreted | Tris-EDTA (pH 9.2) | No | 1:600 | DAKO EnVision+ System, anti-rabbit | Bioss |
| CD31, JC70A | CD31 | Mouse IgG1 | Tissue culture supernatant | Cell membrane | Tris-EDTA (pH 9.2) | No | 1:1000 | MACH-2 Biocare Medical, anti-mouse | Dako |
| CD45, H330 | CD45 | Mouse IgG1 | Affinity chromatography | Cell membrane | Tris-EDTA (pH 9.2) | No | 1:2000 | MACH-2 Biocare Medical, anti-mouse | Biolegend |
| CD4, M1636 | CD34 | Mouse IgG1 | Affinity chromatography | Cell membrane | Citrate (pH 6) | Yes | 1:1 000 000 | MACH-2 Biocare Medical, anti-mouse | Sanquin |
| CD4, H-370 | CD4 | Rabbit IgG | Not specified | Cell membrane | Tris-EDTA (pH 9.2) | No | 1:800 | MACH-2 Biocare Medical, anti-rabbit | Santa Cruz Biotechnology |
| CD8, 8B/144B | CD8 | Mouse IgG1 | Not specified | Cell membrane | Tris-EDTA (pH 9.2) | No | 1:200 | MACH-2 Biocare Medical, anti-mouse | Dako |
| Rabbit IgG | Ref x0903 | Lot 20011861 |  |  |  |  |  |  | Dako |
| Rabbit IgG | Ref I5006 | Lot SLBK1653V |  |  |  |  |  |  | Sigma-Aldrich |
| Mouse IgG | Ref x0931 | Lot 20023783 |  |  |  |  |  |  | Dako |
| Rabbit serum | Ref x0902 |  |  |  |  |  |  |  | Dako |
| Mouse serum | Ref x0910 |  |  |  |  |  |  |  | Dako |

CD indicates cluster of differentiation; and ECM, extracellular membrane.
Table 2. Antibodies Used for Immunofluorescence

| Antibody, Clone | Host Isotype; Subclass | Purification | Cellular Localization | Pretreatment | Protein Block (Dako) | Dilution | Secondary Antibody (+Chromogen If Used) | Reference/Source |
|----------------|------------------------|--------------|-----------------------|--------------|---------------------|----------|------------------------------------------|-----------------|
| CD45, HI30     | Mouse IgG1             | Affinity chromatography | Cell membrane         | Tris-EDTA (pH 9.2) | No | 1:500 | 1. MACH-2 Biocare Medical, anti-mouse 2. Vulcan Red (Biocare Medical, LOT042418) | Dako Biocare Medical |
| CD68, KP1      | Mouse IgG1             | Affinity chromatography | Lysosomes, endosomes, and cell surface | Tris-EDTA (pH 9.2) | No | 1:6000 | 1. Alexa Fluor 488 goat–anti-mouse IgG31 (Life Technologies No. 2121) 2. Alexa Fluor 647 goat–anti-mouse IgG (Invitrogen, Thermo Fisher No. 21241) | Dako Dako |
| CD31, JC70A    | Mouse IgG1             | Tissue culture supernatant | Cell membrane | Tris-EDTA (pH 9.2) | No | 1:500 | Alexa Fluor 546 goat–anti-mouse IgG1 (ThermoFisher No. 2123) | Dako Dako |
| Vimentin, 3B4  | Mouse IgG2a            | Purified from cell culture supernatant | Cytoskeleton (intermediate filament) | Tris-EDTA (pH 9.2) | No | 1:2000 | 1. Alexa Fluor 467 goat–anti-mouse IgG2a (Life Technologies No. 2121) 2. Alexa Fluor 486 goat–anti-mouse IgG1 (Life Technologies No. 2121) | Dako Dako |
| Vimentin, VI-10| Mouse IgM              | Precipitation and chromatography | Cytoplasm | Tris-EDTA (pH 9.2) | No | 1:6000 | Alexa Fluor 488 goat–anti-mouse IgG (Life Technologies No. 21241) | Apcam Dako |
| α-SMA          | Mouse IgG2a            | Purified from cell culture supernatant | Cytoskeleton (actin filaments) | Tris/EDTA (pH 9.2) | No | 1:4000 | Alexa Fluor 647 goat–anti-mouse IgG2a (Life Technologies No. 21241) | Dako Dako |
| FSP-1/S100A4, D9F9O | Rabbit IgG           | Unknown | Nucleus, cytoplasm, and extracellular space | Tris-EDTA (pH 9.2) | No | 1:4000 | Alexa Fluor 647 goat–anti-rabbit IgG3 (Invitrogen, Thermo Fisher No. 31573) | Cell Signaling Technology Dako |
| CD90/Thy-1, ERP3133 | Rabbit IgG         | Tissue culture supernatant | Cell membrane | Tris-EDTA (pH 9.2) | No | 1:2000 | Alexa Fluor 647 goat–anti-rabbit IgG (Invitrogen, Thermo Fisher No. 31573) | Apcam |
| FAP, AF3715    | Sheep IgG             | Antigen affinity purified | Cell membrane | Tris-EDTA (pH 9.2) | No | 1:40 | Alexa Fluor 564 donkey–anti-sheep IgG (ThermoFisher No. 16047) | R&D Systems |
| Paxillin, 5H11 | Mouse IgG1            | Protein G | Cytoplasm > cytoskeleton (local adhesion protein) | Tris-EDTA (pH 9.2) | No | 1:500 | Alexa Fluor 647 goat–anti-mouse IgG31 (Life Technologies No. 21241) | Invitrogen Dako |
| Nonmuscle myosin heavy chain, NBP2-385566 | Rabbit IgG | Immunogen affinity purified | Cytoskeleton (myosin) | Tris-EDTA (pH 9.2) | No | 1:600 | Alexa Fluor 647 donkey–anti-rabbit IgG (Life Technologies No. 31573) | Novusbio |

CD indicates cluster of differentiation; FAP, fibroblast activation protein; FSP-1, fibroblast-specific protein-1; and Thy-1, thymocyte differentiation antigen 1.
Red fluorescence was visualized using a Texas Red Filter (542–582 nm).

**Imaging of Immunofluorescence Slides**

Digital images were acquired using the Panoramic MIDI Digital Slide Scanner (3D HISTECH Ltd, Budapest, Hungary) and analyzed with CaseViewer software (3D HISTECH Ltd). Minor linear adjustments (brightness and contrast) were performed. Nonlinear adjustments were not performed.

Because (partial) overlapping cells may result in pseudocolocalization in widefield optical microscopy, the anticipated pseudocolocalization of CD31 and respectively FSP-1 (fibroblast-specific protein-1)/thymocyte differentiation antigen 1 (Thy-1)/FAP (fibroblast activation protein), as well as the anticipated genuine colocalization of CD45 and vimentin, was validated by confocal microscopy (Zeiss LSM 800 CLSM, Oberkochen, Germany). Image analysis was performed with ZEN Lite (Zeiss).

**RESULTS**

**Literature Review**

**Identification of Phenotypical Immunohistochemistry Markers**

The search strategy identified 3246 articles after removal of duplicates, 655 of which were considered of potential relevance (Figure 2 [Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram]). Potentially relevant articles mainly addressed SMC differentiation (n=559 articles), and to a lesser extent aspects of (myo)fibroblastic or mesenchymal differentiation (96 articles). The abstracts of these latter 96 articles were all assessed for potential relevance. Given the large number of publications on SMC

![Flowchart](chart.png)

Legend:
- **Identification**
  - Records identified through database searching (n=4069)
  - Additional records identified through other sources (n=2)
  - Records after duplicates removed (n=3246)
  - Potentially relevant abstracts (n=655)
  - SMC (n=559)
  - (M)FB/Mes* (n=96)
  - Potentially relevant abstracts n=113
    - Reviews n=69
    - Art ≥18 n=44
  - Potentially relevant abstracts n=96

- **Screening**
  - Records excluded (n=15)
  - Potentially relevant abstracts n=98
  - Relevant abstracts n=92

- **Eligibility**
  - Relevant abstracts (n=91)
  - Full-text articles assessed for eligibility (n=190)
  - Full-text articles excluded (n=10), with reasons:
    - n=1: no full text available in LUMC
    - n=8: no differentiation markers described
    - n=1: conference proceeding

- **Inclusion**
  - Studies included in qualitative synthesis (n=180)

---

**Figure 2.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for selection of articles on phenotypical mesenchymal markers.

SMC indicates smooth muscle cell.
determination (n=559), it was decided for an alternative approach by focusing on all review articles for assessment of the abstracts (n=69). Because the most recent review was published in March 2018, we additionally screened abstracts of articles published after January 2018 (n=44). On exclusion of articles deemed not relevant for this study, the abstract screening resulted in 190 potentially relevant articles, of which 180 full-text articles were included for the qualitative synthesis. Motivation for noneligibility of full-text articles is provided in Table S1.

The identified markers were included for further evaluation (Table 3) if at least 3 independent studies referenced them. Markers excluded in this evaluation are summarized in Table S2. All in all, this strategy yielded 16 candidate markers (either lineage or differentiation specific), which are summarized in Table 3.

**Cell Identity Markers**

On the basis of the literature, identified markers were classified as (mesenchymal) lineage or (sub)class specific (ie, potentially discriminating between fibroblasts, myofibroblasts, or SMCs). The literature synopsis did not indicate a discriminatory marker(set) for myofibroblasts versus SMCs (Table 3), nor a single fibroblast-specific marker.

In this context, it was decided to categorize the identified markers along the following lines: we first defined a group of 4 markers that are reported as lineage specific (eg, vimentin) and a second group consisting of 3 markers associated with the principal force generating machinery (α-smooth muscle actin [αSMA], the 2 smooth muscle myosin heavy chain [SM-MHC] isoforms [SM1 and SM2], and nonmuscle myosin heavy chain [Smemb]). This cluster may allow differentiation between contractile (expressed in both SMC-like and myofibroblastic classes) and noncontractile mesenchymal cells.

A third group constituted of 7 molecules that are accessory to the contractile machinery (eg, tropomyosin). The final 2 markers (final fourth subset) are associated with cell-cell and/or cell-matrix interactions (eg, vinculin).

**Markers of Functional Status**

The literature review for candidate functional markers (ie, proinflammatory and synthetic markers) in the context of vascular biology research identified 222 full-text articles (Figure 3). Motivation for noneligibility of the reviewed full-text articles is provided in Table S3. Again, a threshold of at least 3 independent references for each functional marker was adopted to include the marker for immunohistochemistry evaluation (Tables S4 and S5).

On the basis of this search strategy, 8 synthetic and 4 proinflammatory markers were selected for further evaluation (Table 4).

**Histological Validation**

**Interference by Rabbit Polyclonal Antibodies**

A particular point of concern that emerged from the histological evaluation was an apparent interference when using rabbit polyclonal antibodies on formalin-fixed, paraffin-embedded vessel wall samples. Interference was consistent for different sources and batches of isotype controls, and found for rabbit serum (Figure S2). In fact, all rabbit immunoglobulins in concentrations beyond 1 μg/mL produced a characteristic staining pattern on the arterial wall samples. This phenomenon was rabbit IgG/serum specific. Consequently, we avoided the use of rabbit polyclonal antibodies requiring working dilutions of ≥1 μg/mL in this evaluation.

**Vascular Distribution and Specificity**

We validated the expression patterns and staining specificity of the phenotypical and functional cell markers identified in the literature review on the vessel wall samples from the biobank. All markers selected in the review process were stained (single staining) on consecutive slides of the reference tissue block. Results from the evaluation (summarized as semiquantitative scores for the different aspects of the arterial wall) are summarized in Figure 4.

**Lineage (mesenchymal) markers**

Vimentin, FSP-1/S100A4, Thy-1/CD90, and FAP were identified as mesenchymal lineage-specific markers (Figure 5A).

All 4 markers were diffusely expressed throughout the vessel wall and vasa vasorum in the early atherosclerotic (AIT) reference sample. However, a notable inconsistent expression was found for these markers in the media, with subsets of spindle-shaped cells being vimentin+ and FAP+, but negative for both FSP-1 and Thy-1, challenging Thy-1 and FSP-1 as generic mesenchymal lineage markers. Indeed, validation of this observation in triple immunofluorescence stainings of (Thy-1/FSP-1/FAP)/vimentin/αSMA showed that up to 10% of the spindle-shaped αSMA+/vimentin+ or αSMA+/FAP+ cells in the media were negative for both Thy-1 and FSP-1 (Figure S3).

This dissociation between vimentin and Thy-1 expression became even more pronounced in the more advanced atherosclerotic stages by an apparent inverse association between Thy-1 expression and disease progression, with a particularly low expression of...
### Table 3. Overview of Selected Potential Phenotypic Markers

| Antibody* | Function† | Specificity in Vasculature† | Fibroblastic Cells | Myofibroblastic Cells | C-SMCs |
|-----------|-----------|----------------------------|--------------------|-----------------------|--------|
| **Mesenchymal lineage** | | | | | |
| 1. Vimentin12-14 | Stabilization of cytoskeletal interactions and maintenance of cell shape and integrity of the cytoplasm15,16 | Expressed in leukocytes and endothelial cells as well20,21 | | | |
| 2. S100A4/FSP-115-17 | Involved in proteolytic activity during ECM remodeling and cell migration, proliferation, differentiation, and contractility22-24 | Expressed in leukocytes as well20,25,26,27 | | | |
| 3. CD90/Thy-115,19 | Involved in cell adhesion and cell communication28 | Expressed in endothelial cells as well29 | | | |
| 4. FAP20-22 | Thought to promote cellular invasion through the ECM30 | Expressed in leukocytes as well20,21 | | | |
| **Contractile apparatus** | | | | | |
| 5. αSMA23-25 | Force generation30,31,32 | Expressed in macrophage-like phenotype (foam cells) as well22,23,24 | | | |
| 6. Smemb25-27 | Thought to be involved in diverse processes, including cytokinesis, cell shape, and secretion33,34,35 | Restricted to mesenchymal cells36 | | | |
| 7. SM-MHC28-30 | Force generation30,31,32 | Restricted to mesenchymal cells30,31,32 | | | |
| **Accessory contractile** | | | | | |
| 8. h1-Calponin28,31,32 | Regulation and modulation of smooth muscle contraction30,31,32 | Restricted to mesenchymal cells30,31,32 | | | |
| 9. h-Caldesmon31,33,34 | Regulation of smooth muscle contraction31,32 | Restricted to mesenchymal cells31,32 | | | |
| 10. Desmin33,34,35 | Maintenance of myofibril, myofiber, and whole muscle tissue structural and functional integrity33,34,35 | Restricted to mesenchymal cells (in vasculature)33,34,35 | | | |
| 11. SM22α22,28,29 | Involved in the reorganization of the actin cytoskeleton and cell contractility36,37 | Restricted to mesenchymal cells36,37 | | | |
| 12. Smoothelin-B38-39,40 | Associates with stress fibers and constitutes part of the cytoskeleton38,39 | Restricted to mesenchymal cells38,39 | | | |
| 13. a-Tropomyosin37,38,39 | Regulation of smooth muscle contraction30,31,32 | Restricted to mesenchymal cells30,31,32 | | | |
| 14. Telokin40-42 | Involved in initiation or maintenance of smooth muscle relaxation as well as in contraction40-42 | Restricted to mesenchymal cells40-42 | | | |
| **Focal adhesion** | | | | | |
| 15. Paxillin43-45 | Focal adhesion protein involved in cell-matrix adhesion and presumably coordination of transmission of downstream signals in cell movement and migration46 | Expressed in leukocytes, endothelial cells, and epithelial cells as well47,48 | | | |
| 16. Vinculin36,37,49 | F-actin binding protein involved in cell-matrix adhesion and cell-cell interactions49 | Expressed in leukocytes, endothelial cells, and epithelial cells as well49 | | | |

The selected phenotypical markers are divided in 3 main groups, of which the contractile markers are subdivided on the basis of whether they are part of the contractile apparatus or they are accessory proteins that regulate actin-myosin interaction. Fibroblastic cells, myofibroblastic cells, and C-SMCs were evaluated on their reported discriminative power: dark gray represents controversy over discriminating ability of the marker, and light gray represents consensus that the marker is nondiscriminative. CD indicates cluster of differentiation; C-SMC, contractile smooth muscle cell; ECM, extracellular membrane; FAP, fibroblast activation protein; FSP-1, fibroblast-specific protein-1; αSMA, α-smooth muscle actin; SM22α, smooth muscle protein 22α; Smemb, nonmuscle myosin heavy chain; SM-MHC, smooth muscle myosin heavy chain; and Thy-1, thymocyte differentiation antigen 1.

*References from systematic review.
†Supplementary references (not from systematic review).
Thy-1 in the neointima. Further discrepancies were observed for vimentin and FAP. Although medial vimentin expression remained stable in advanced-stage (LFA) atherosclerotic disease samples, FAP expression varied (Figure S4).

For explorative purposes, we also evaluated vimentin and αSMA coexpression in the cap of progressive lesions (ie, LFA and the unstable progressive atherosclerotic lesion [thin cap fibroatheroma]), as well as a stabilized lesion type (HR) (Figure S5). The cap in LFA was rich in mesenchymal cells (elongated vimentin+ cells). Transition to a thin cap fibroatheroma was associated with a clear decrease in cap cell density. In both LFA and thin cap fibroatheroma, ≈80% of the vimentin+ cells were double vimentin+/αSMA+. Similarly, 80% of the vimentin+ cells in the cell-rich/proteoglycan-rich luminal granulation tissue associated with healing of a ruptured atherosclerotic lesion (HR) were double vimentin+/αSMA+.

On the basis of these observations, vimentin classified as the most inclusive lineage marker. However, we did observe a small population of spindle-shaped FAP+/vimentin+ cells in the cap of LFA (Figure S4.2), defying vimentin as an all-inclusive panmesenchymal marker.

Specificity of vimentin as a mesenchymal lineage marker was challenged by the diffuse presence of round, vimentin+ cells in the vicinity of the vasa vasorum in the adventitia. Validation studies that included triple immunofluorescence staining for the panleucocyte marker CD45, the macrophage marker CD68, and vimentin showed subsets of triple-positive cells in the adventitia (Figure S6.1/2). This colocalization was observed for different vimentin antibodies, and confirms the expression of vimentin in subsets of macrophages. Along similar lines, we identified (small) subsets CD45+/CD68+ and FSP-1+, Thy-1+, or FAP+ triple-positive cells in the adventitia, consistent with subsets of FSP-1+, Thy-1+, and FAP+ macrophages (Figure S6.3-5).

Moreover, indications were found for vimentin expression in subsets of endothelial cells. Endothelial cell-specific expression was confirmed by CD31/vimentin double staining (Figure S7). Confocal microscopy characterized the apparent spatial associations between CD31 and FSP-1, Thy-1, and FAP as pseudo-colocalization. Distinct, small populations of solitary vimentin+/CD31+ and vimentin+/CD34+ were observed in the vicinity of the adventitial vasa vasorum (Figure S8).

A third nonclassic population of vimentin+ cells was observed in the granulation tissue of HR. Approximately 10% of these spindle-shaped cells were double VIM+/CD45+(Figure S9.1). Incidental (<5% of the population)
double Vim+/CD45+ cells were also observed in the cap and neointima of LFA and FCP reference sections. Distinct (spindle-shaped and round) morphological features may imply distinct subpopulations (Figure S9.2/3).

Contrastive/noncontrastive phenotype markers
dSMA, SM-MHC (isofoms SM1 and SM2), and Smemb (embryonic form of SM-MHC) are principal parts of the contrastive machinery that is characteristic for SMCs and myofibroblasts (Figure 5B).

dSMA was expressed in virtually all spindle-shaped cells in the intima, media, and adventitia. In mesenchymal cells covering the vasa vasorum, dSMA was consistently expressed. Expression of the SM-MHC isoforms and Smemb was more variable: SM-MHC (SM1) expression was notably less in the middle section of the media than in the inner and outer segments of the media, and expression of the second isoform (SM2) was limited to the outer segment of the media. Smemb expression was more pronounced in the outer medial segment than in other medial segments. A discriminatory expression profile was seen for SM-MHC/Smemb expression in the vasa vasorum with parallel expression in the thick-walled arteriole-like vessels, but Smemb single positivity was found in the thin-walled venule-like vessels.

Progressive stages of atherosclerosis showed stable dSMA expression, whereas SM-MHC and Smemb expression were negatively and positively associated, respectively, with disease progression, potentially disqualifying SM-MHC and Smemb as all-encompassing

| Table 4. Overview of Selected Potential Functional Markers |
| --- |
| Subdivision | Antibody, Reference | Function | Tested Immunohistochemistry |
| Synthetic | 1. Collagen type | Provides tensile strength of the arterial wall | Nonspecific staining |
| Synthetic | 2. Procollagen type | Precursor of collagen 1, the most abundant collagen in ECM | Weak to no staining, in higher concentrations, nonspecific staining |
| Synthetic | 3. Prolyl 4-hydroxylase | Involved in hydroxylation of prolyl residues in procollagen | Works well |
| Synthetic | 4. Osteopontin | Mediates cell migration, adhesion, and survival of SMCs and endothelial cells and functions as Th1 cytokine | Works well, but extracellular presence hampers cell phenotyping |
| Synthetic | 5. Fibronectin | ECM constituent with great diversity of cellular functions, including adhesion, cytoskeletal organization, migration, growth, and differentiation | Works well, but extracellular presence hampers cell phenotyping |
| Synthetic | 6. Laminin | ECM constituent (base membrane) with great diversity of cellular functions, including adhesion, migration, differentiation, and proliferation | Works well, but extracellular presence hampers cell phenotyping |
| Synthetic | 7. CRBP-1 | Regulation of uptake, intracellular transport, and metabolism of retinol | No protein expression detectable in AAA and atherosclerotic tissue |
| Synthetic | 8. PDGFR-α | PDGF-α is a mitogen for mesenchymal cells and regulates proliferation, migration, and differentiation during embryonic development | Nonspecific staining |
| Proinflammatory | 9. NF-κB | Pivotal mediator of inflammatory responses by inducing proinflammatory genes and regulating the survival, activation, and differentiation of innate immune cells and inflammatory T cells | Low protein expression in vessel wall |
| Proinflammatory | 10. Interleukin 6 | Proangiogenic and proinflammatory cytokine, predominantly associated with plasma cells and macrophages | Works well |
| Proinflammatory | 11. MCP-1 | Regulates migration and infiltration of monocytes/macrophages | No protein expression detectable in AAA and atherosclerotic tissue |
| Proinflammatory | 12. Interleukin 8 | Proangiogenic and proinflammatory cytokine, predominantly associated with lymphocytes and neutrophils; promotes neutrophil infiltration and activation, and can exert strong proangiogenic activities | Works well |

AAA, abdominal aortic aneurysm; CRBP-1 indicates cellular retinol-binding protein 1; ECM, extracellular membrane; MCP-1, monocyte chemoattractant protein 1; NF-κB, nuclear factor-κB; PDGF-α, platelet-derived growth factor α; PDGFR-α, PDGF-α receptor; SMC, smooth muscle cell; and Th1, T-helper type 1 T-cell.
Heterogeneous responses were seen for the auxiliary contractile markers in the context of the atherosclerotic disease progression: Smoothelin and Desmin expression related inversely to disease progression, whereas medial expression of h1-Calponin, h-Caldesmon, SM22α, Tropomyosin, and Telokin remained stable. H1-Calponin+, Tropomyosin+, Telokin+, and SM22α+ were present in subsets of mesenchymal cells in the cap/shoulder, and in the neointima regions in LFA and FCP. A subpopulation (<10%) of spindle-shaped Tropomyosin+ αSMA− cells was observed in the cap of the LFA lesion (Figure S13).

**Focal adhesion proteins: vinculin and paxillin**

The fourth cluster of markers included Vinculin and Paxillin, molecules involved in cell-cell and cell-matrix interactions (Figure 5D). In AIT, they were both abundantly expressed in the intimal and outer medial zone and to a lesser extent in the inner and middle media. Although Paxillin expression was also observed in double CD45+/Vimentin+ cells in the adventitia (Figure S12.3), Vinculin expression was absent in the adventitia. Although Paxillin expression remained stable during atherogenic progression, Vinculin expression decreased during disease progression.

**Functional markers**

Apart from their phenotypical identities, mesenchymal cells can be actively involved in matrix deposition and homeostasis (synthetic phenotype), and may adapt an inflammatory phenotype. We evaluated several markers for a synthetic or an inflammatory phenotype (results are summarized in Table 4).

On the basis of an evaluation of compatibility with immunohistochemistry-based subtyping, which involved a preferably intracellular staining pattern and availability of antibodies compatible with paraffin-embedded material, the signal/background ratio, and specificity, it was decided for P4HB and interleukin 6 (IL-6) or interleukin 8 (IL-8; aka, CXCL8) as preferred markers for a secretory inflammatory phenotype. Motivations for refraining from the other candidate markers are provided in Figure S14.

IL-6 and IL-8 expression was used to visualize inflammatory status of the mesenchymal cell population (Figure 5E): in AIT, IL-6 and IL-8 expression was observed for infiltrating mesenchymal cells in the intima, and in subsets of adventitial mesenchymal cells. IL-8 was expressed in the media-adventitial border as well. Increased medial IL-6 and IL-8 expression, and significant expression of IL-6 and IL-8 in the cap and shoulder regions, was observed during atherogenic progression.

Expression of these inflammatory markers in the mesenchymal cell population may reflect the inflammatory character of atherosclerosis, an aspect that is
Figure 5. Histological validation of the selected immunohistochemistry (IHC) markers.

**A**, Mesenchymal lineage IHC markers. Overview of staining patterns in the selected representative atherosclerotic sections of adaptive intimal thickening (AIT) (early), late fibroatheroma (LFA) (progressive), and fibrotic calcified plaque (FCP) (end stage). Close ups in LFA and FCP represent cap regions and neointima, respectively. **B**, Generic contractile IHC markers. Overview of staining patterns in the selected representative atherosclerotic sections of AIT (early), LFA (progressive), and FCP (end stage). Close ups in LFA and FCP represent cap regions and neointima, respectively. **C**, Accessory contractile IHC markers. Overview of staining patterns in the selected representative atherosclerotic sections of AIT (early), LFA (progressive), and FCP (end stage). Close ups in LFA and FCP represent cap regions and neointima, respectively. **D**, Focal adhesion IHC markers. Overview of staining patterns in the selected representative atherosclerotic sections of AIT (early), LFA (progressive), and FCP (end stage). Close ups in LFA and FCP represent cap regions and neointima, respectively. **E**, Interleukin 6 (IL-6) and interleukin 8 (IL-8) staining (activation markers). Overview of staining patterns in the selected representative atherosclerotic sections of AIT (early), LFA (progressive), and FCP (end stage). Close ups in LFA and FCP represent cap regions and neointima, respectively. **F**, Prolyl 4-hydroxylase β (P4HB) staining (synthetic marker). Overview of staining patterns in the selected representative atherosclerotic sections of AIT (early), LFA (progressive), and FCP (end stage). Close ups in LFA and FCP represent cap regions and neointima, respectively. CD indicates cluster of differentiation; FAP, fibroblast activation protein; FSP, fibroblast-specific protein; α-SMA, α-smooth muscle actin; SM22α, smooth muscle protein 22α; Smemb, nonmuscle myosin heavy chain; SM-MHC, smooth muscle myosin heavy chain; and Thy1, thymocyte differentiation antigen 1.
P4HB, an enzyme involved in (pre) collagen processing, was identified as preferred marker for a synthetic phenotype (Figure 5F). Expression of P4HB was confined to the intima and, with the exception of some vasa vasorum absent in the media and adventitia, in early-stage atherosclerosis. In more advanced stages of atherosclerosis, P4HB expression was observed in the cap and shoulder regions, as well as in the adventitial venule-like and arteriole-like vasa vasorum. P4HB remained absent in the entire media.

On the basis of the tentative results of the review and the inventory, a proposed marker set was compiled for an explorative evaluation of the vascular mesenchymal landscape (Tables 5 and 6).

**DISCUSSION**

The vascular mesenchymal landscape appears to be highly dynamic, diverse, and complex. It extends far beyond the classic tripartite classification scheme of fibroblasts, myofibroblasts, and SMCs. Furthermore, there is no evidence for a clear separation along the lines of myofibroblast and SMC populations. These

---

**Figure 5. Continued**

|  | AIT | LFA | FCP |
|---|---|---|---|
| **α-SMA** | ![Image](image1.png) | ![Image](image2.png) | ![Image](image3.png) |
| **Smemb** | ![Image](image4.png) | ![Image](image5.png) | ![Image](image6.png) |
| **SM-MHC (SM1)** | ![Image](image7.png) | ![Image](image8.png) | ![Image](image9.png) |
| **SM-MHC (SM2)** | ![Image](image10.png) | ![Image](image11.png) | ![Image](image12.png) |
findings for the human context confirm and extend observations for murine models of atherosclerosis that imply an extremely diverse spectrum of mesenchymal cells within the vessel wall.\textsuperscript{129,130}

---

**Figure 5.** Continued
Mesenchymal cells are the pivotal cellular component of load-bearing structures and organs. They are the principle component of blood vessels, where they modulate vascular tone and maintain vascular integrity through deposition and maintenance of the extracellular matrix.\textsuperscript{131,132} As a consequence, mesenchymal cells are in the center of vascular pathological conditions, such as atherosclerosis and aneurysmal disease.\textsuperscript{133,134} In fact, mesenchymal cell activation and migration in response to intimal lipoprotein deposition is the initiating step in the human atherosclerotic process.\textsuperscript{135} Data from murine atherosclerotic models suggest that SMCs contribute the majority of foam cells.\textsuperscript{136} In the more advanced stages of atherosclerotic disease, mesenchymal cells critically contribute to plaque stability, as well as to aspects such as vascular calcification and intimal hyperplasia.\textsuperscript{137,138} Indeed, an exploratory inventory implied clear qualitative changes in the cap during plaque progression with a nadir in cell density in thin cap lesions, but recovery of mesenchymal cell density (elongated vimentin\textsuperscript{*} cells) in the cell-rich/matrix-rich granulation tissue of a healed rupture.

Along similar lines, mesenchymal cells are key players in both genetic (eg, thoracic aneurysms associated
with bicuspid valve disease and degenerative aneurysms, such as the abdominal aortic aneurysm. For the latter, impaired mesenchymal differentiation has been directly linked to aneurysm rupture.

The vascular mesenchymal landscape is particularly complex, not only as a reflection of the heterogeneous embryological origin of the vascular tree, and the vascular layers, but also because SMCs are nonterminally differentiated, thus allowing a high degree of phenotypical plasticity. Moreover, it is now clear that processes, such as endothelial-to-mesenchymal transition, contribute to the vascular mesenchymal population.

Evidence was also found for the presence of fibrocytes. Ample elongated double CD45+/vimentin+ cells were observed in the process of cap healing following plaque rupture, and in the neointima overlaying a fibrous lesions. Moreover, we observed subpopulations of round and spindle-shaped double CD45+/vimentin+ cells in the cap of LFA. This observation is consistent with the (co)existence of distinct subpopulations of double CD45+/vimentin+ cells in the atherosclerotic process: spindle-shaped fibrocytes, which could be consistent with the phenomenon of leukocyte-mesenchymal transition and the round cells possibly representing a subclass of macrophages.

The immunological field has benefited enormously from the introduction of the consensus classification of leukocyte subtypes, based on well-defined marker sets (CD markers); such classification system does not exist for mesenchymal cells. In a first attempt toward a mesenchymal cell classification for the vasculature, we inventoried candidate subtype markers through a literature review, and mapped the identified markers on a set human aorta specimens with successive stages of the atherosclerotic process.

The literature review identified 4 mesenchymal lineage markers: vimentin, FSP-1/S100A4, Thy-1/CD90, and FAP. Validation stainings disqualified FSP-1/S100A4 and Thy-1/CD90 as universal mesenchymal lineage markers. Therefore, conclusions based on studies relying on these markers may be incomplete.

On the basis of its performance in this evaluation, and on the assumption that most spindle-shaped cells are mesenchymal cells, vimentin classified as the preferred mesenchymal lineage marker for the vasculature because this was the most inclusive marker for spindle-shaped cells in the media. However, histological stainings identified small subsets of vimentin+/FAP+ cells in specific niches, suggesting that vimentin may not be fully inclusive and that a comprehensive appreciation of the full mesenchymal spectrum may rely on the vimentin/FAP dual-marker set.

On the same token, vimentin expression was seen in subset(s) of vascular macrophages, as well as the endothelial lining of vasa vasorum, indicating that vimentin is not fully mesenchymal cell specific, and that full specificity relies on costaining of exclusion markers (eg, CD31 and CD68). This study also identified

| Phenotype | Function | Pathological Conditions |
|-----------|----------|------------------------|
| Generic mesenchymal: FAP+ / vimentin+ /CD31+/ CD45+ | Contractile, generic*: αSMA+/ tropomyosin | Synthetic: P4HB+ |
| | | Proinflammatory: IL-6+/ IL-8+ |
| Noncontractile: αSMA+/ tropomyosin | | EndoMT/stem cells: CD34+ |
| | | CD31+ |
| | | LeucoMT: CD45+ |

Table 6. Proposed Marker Set for Comprehensive Inventory of Mesenchymal Cell Populations in Human Vasculature

| Phenotype | Function | Pathological Conditions |
|-----------|----------|------------------------|
| Generic mesenchymal: FAP+/vimentin+/CD31+/CD45+ | Contractile, generic*: αSMA+/ tropomyosin | Synthetic: P4HB+ |
| | | Proinflammatory: IL-6+/ IL-8+ |
| Noncontractile: αSMA+/ tropomyosin | | EndoMT/stem cells: CD34+ |
| | | CD31+ |
| | | LeucoMT: CD45+ |

Construction scheme of proposed mesenchymal marker set selection. Suggestions for well-working antibodies are provided in Table 1. To acquire ≈99% inclusivity for mesenchymal cells, a dual-marker set of vimentin+/FAP+ (possibly as costaining, stained by the same chromogen) is needed. Likewise, for contractile mesenchymal cells, the dual-marker set αSMA+/Tropomyosin reaches ≈99% inclusivity. CD indicates cluster of differentiation; EndoMT, Endothelial-to-Mesenchymal cell Transition; FAP, fibroblast activation protein; IL-6, interleukin 6; IL-8, interleukin 8; LeucoMT, Leucocyte-to-Mesenchymal cell Transition; P4HB, prolly 4-hydroxylase β; and αSMA, α-smooth muscle actin.

*For a list of accessory contractile and focal adhesion markers, see Table 3.

†OR/AND.

Table 5. Proposed Marker Set for Standard Inventory of Mesenchymal Cell Populations in Human Vasculature

| Phenotype | Function | Pathological Conditions |
|-----------|----------|------------------------|
| Generic mesenchymal: vimentin+/CD31+/CD45- | Contractile, generic*: αSMA+ | Synthetic: P4HB+ |
| | | Proinflammatory: IL-6+/ IL-8+ |
| | | EndoMT/stem cells: CD34+ |
| | | CD31+ |
| | | LeucoMT: CD45+ |

Construction scheme of proposed mesenchymal marker set selection. Suggestions for well-working antibodies are provided in Table 1. Vimentin, in a marker set with CD31+/CD45+, will identify >95% of mesenchymal cells. αSMA will identify >95% of contractile mesenchymal cells. CD indicates cluster of differentiation; EndoMT, Endothelial-to-Mesenchymal cell Transition; IL-6, interleukin 6; IL-8, interleukin 8; LeucoMT, Leucocyte-to-Mesenchymal cell Transition; P4HB, prolly 4-hydroxylase β; and αSMA, α-smooth muscle actin.

*For a list of accessory contractile and focal adhesion markers, see Table 3.

†OR/AND.
solitary double vimentin+CD31+ and vimentin+/CD34+ cells in the vicinity of adventitial vasa vasorum, possibly identifying vascular stem cells or cells in Endothelial-to-Mesenchymal cell Transition.149

Next to the lineage markers, the review identified several subclass markers. Markers for contractile phenotype were subdivided in 2 closely related subgroups: principal constituents of the contractile apparatus (αSMA, SM-MHC, and Smemb) and its auxiliary molecules (ie, actin/myosin interaction regulating h1-Calponin, Desmin, h-Caldesmon, Tropomyosin, Telokin, Smoothelin, and SM22α).

αSMA classified as the most inclusive marker for presence of a professional contractile machinery. However, coverage of the full spectrum of contractile mesenchymal cells may require a dual-marker set of αSMA/Tropomyosin, as the histological evaluation identified small specific niches in the cap of LFA that contained spindle-shaped αSMA−/Tropomyosin+ cells.

Smemb has been linked to a synthetic phenotype. Indeed, a subset of elongated Smemb+ in the shoulder and cap of progressive atherosclerotic lesions also expressed P4HB. Yet, Smemb+/P4HB− elongated cells were abundantly present in the media of early-stage atherosclerosis. These observations characterize Smemb as a mere differentiation marker.

A considerable degree of coexpression was observed for the auxiliary contractile markers in early atherosclerotic disease (AIT). However, increased heterogeneity was observed for the progressive stages. Clear spatial distribution of these subpopulations implies some form of synchronization in the processes of subdifferentiation. Exploration of underlying molecular synchronization pathways and functional diversity of the subdifferentiated cells is beyond the scope of this inventorying exploration.

The literature review further identified the focal adhesion proteins Vinculin and Paxillin, a binding partner of Vinculin,150 as markers of mesenchymal differentiation. These proteins do not associate with the contractile apparatus, but are involved in environmental sensing,151 and are abundantly expressed by mesenchymal cells in the normal vessel wall.152 We observed downregulation of Vinculin in spindle-shaped cells in the media during atherogenic progression, a phenomenon that has been interpreted as an indication of disturbed intermesenchymal or mesenchymal-extraacellular matrix interaction.153

The identification of functional markers set for histological phenotyping came with several technical challenges. The inflammatory spectrum is notably broad, thus interfering with the identification of a generic marker. Moreover, by virtue of the responsive and adaptive nature of the inflammatory, protein expression can be extremely low and volatile, thus creating suboptimal conditions for immunohistochemistry. The cytokines/chemokines IL-6 and IL-8 (both essentially controlled by nuclear factor-kB activity) can be present as intracellular stores, and thus are well identifiable by immunohistochemistry staining. On this basis, we evaluated their potential as markers of (aspects of) an inflammatory phenotype. Indeed, IL-6 and IL-8 were both particularly upregulated in lesional intimas, such as the cap and shoulder regions of LFA. The dynamics of the innate and adaptive cellular immune response in human atherosclerosis have been extensively reported previously.154,155

Along similar lines, challenges exist for markers of a synthetic, secretory phenotype. Histological staining of deposited matrix products results in a profound extracellular staining pattern that interferes with the interpretation of intracellular stainings. Our evaluation identified the (pre)collagen processing enzyme PH4B as the optimal marker for mapping a synthetic phenotype in immunohistochemistry. In AIT, P4HB expression was confined to the intima, with the exception of some vasora, and showed upregulation during atherogenic progression in lesional intimas, such as the cap and shoulder regions in LFA.

Because our literature review did not provide conclusive evidence with respect to a discriminatory marker set identifying the classic smooth muscle phenotype and myofibroblast phenotype, it was reasoned that the arteriolar smooth muscle cell of the vasa vasorum in the adventitia constitutes the best reference to the classic, functionally contractile SMC phenotype. On basis of this premise, we could not establish a clear separation along the lines of myofibroblastic and SMC populations based on the (auxiliary) contractile markers.

As (my)fibroblastic cells are characterized by their ability to synthesize collagen, P4HB was explored as discriminative factor. However, spindle-shaped P4HB+ cells covering the vasa vasorum were found as well.

This may suggest that myofibroblasts are rather cell states of fibroblastic cells or SMCs than a discrete cell type.

This evaluation of the mesenchymal landscape on the basis of a parallel evaluation of >25 markers indicates a spatially diverse, highly dynamic, and heterogeneous panorama. The spatial diversity and extreme granularity, and the relative long protein half-lives for most markers, pose particular challenges to RNA-based analysis, and to techniques relying on tissue dissection and clustering, such as single-cell analysis. Although immunohistochemistry has a clear advantage to these challenges, this explorative study has some limitations as well. First, the study is based on the results of a literature review. As such, the evaluation may be incomplete and findings from in vitro
ARTICLE INFORMATION

Received April 27, 2020; accepted October 5, 2020.

Affiliations
From the Division of Vascular Surgery, Department of Surgery (L.E.B., C.M.v.R., J.F.H., J.H.L.) and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands (B.E.v.d.A.).

Acknowledgments
The authors wish to kindly thank J.W. Schoonens for his assistance in composing the search strategy.

Sources of Funding
None.

Disclosures
None.

Supplementary Material
Datas S1–S3
Tables S1–S5
Figures S1–S15
References 2,3,5,23,57,61,109,133,143,156-311

REFERENCES
1. Topouzis S, Majesky M. Smooth muscle lineage diversity in the chick embryo. Dev Biol. 1996;178:430–445.
2. Lacolley P, Reignault V, Nicoletti A, Li Z, Michel J. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012;95:194–204.
3. Riches K, Clark E, Hellwell RJ, Angelini TG, Hemmings KE, Bailey MA, Bridge KI, Scott DJA, Porter KE. Progressive development of aberrant smooth muscle cell phenotype in abdominal aortic aneurysm disease. J Vasc Res. 2018;55:35–46.
4. Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol. 2011;57:376–379.
5. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858–870.
6. Johnson RJ, Flejoe J, Yoshimura A, Iida H, Couser WG, Alpers CE. The activated mesangial cell: a glomerular “myofibroblast”? J Am Soc Nephrol. 1992;2:S190–S197.
7. Di Carlo SE, Peduto L. The perivascular origin of pathological fibroblasts. J Clin Invest. 2018;128:54–63.
8. Gibbons G, Dzau V. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431–1438.
9. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, De Wever O, Mareel M, Gabbiani G. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180:1340–1355.
10. Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, Joner M, Virmani R. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016;13:79–98.
11. Kao HK, Chen B, Murphy GF, Li Q, Orgill DP, Quo L. Periphereal blood fibrocytes: enhancement of wound healing by cell proliferation, re-epithelialization, contraction, and angiogenesis. Ann Surg. 2011;254:1066–1074.
12. Chai X, Sun D, Han Q, Yi L, Wu Y, Liu X. Hypoxia induces pulmonary arterial fibroblast proliferation, migration, differentiation and vascular remodeling via the PI3K/Akt/p70S6K signaling pathway. Int J Mol Med. 2018;41:2461–2472.
13. Wilcox JN, Okamoto EI, Nakahara KI, Vinten-Johansen J. Perivascular responses after angioplasty which may contribute to postangioplasty restenosis: a role for circulating myofibroblast precursors? Ann N Y Acad Sci. 2001;947:68–90.
14. Onuta G, van Ark J, Rienstra H, Boer MW, Klatter FA, Bruggeman CA, Zeelbergts CJ, Rozing J, Hillebrandts JL. Development of transplant vasculopathy in aortic allografts correlates with neointimal smooth muscle cell proliferative capacity and fibrocyte frequency. Atherosclerosis. 2010;209:393–402.
15. Kuwabara JT, Talloquist MD. Tracking adventitial fibroblast contribution to disease: a review of current methods to identify resident fibroblasts. Arterioscler Thromb Vasc Biol. 2017;37:1598–1607.
16. Witt W, Büttner P, Jannasch A, Martschke K, Waldow T. Reversal of myofibroblastic activation by polyunsaturated fatty acids in valvular interstitial cells from aortic valves: role of PPAR-γ in vivo. J Mol Cell Cardio. 2014;74:127–138.
17. Wang G, Jacquet L, Karamariti E, Xu Q. Origin and differentiation of vascular smooth muscle cells. J Physiol. 2015;593:3013–3030.
18. Covas DT, Panepucci RA, Fontes AM, Silva WA Jr, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol. 2008;36:642–654.
19. Qian J, Tian W, Jiang X, Tamosiuniene R, Sung YK, Shuffle EM, Tu AB, Valenzuela A, Jiang S, Zamanian RT, et al. Leukotriene B4 activates monocyte lineage cells to differentiate into myofibroblasts in vitro. J Appl Physiol. 2008;105:2307–2315.
20. Kovacic JC, Dimmelser S, Harvey RP, Finkel T, Aikawa E, Krenning G, Baker AH. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:190–209.
21. Evard SM, Lecece L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR, Descamard V, Li JR, Hadir L, Fujitani K, et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun. 2016;7:11853.
Madden JA, Dempster MJ, McCarron JG. The transition of smooth muscle cells from a contractile to a migratory, phagocytic phenotype: direct demonstration of phenotypic modulation. J Physiol. 2016;594:8189–8209.

Frangogiannis NG, Michael LH, Entman ML. Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (SMemb). Cardiovasc Res. 2000;48:89–100.

Akawa M, Sivam PN, Kuro-o M, Kimura K, Nakahara K, Takewaki S, Ueda M, Yamaguchi H, Yazaki Y, Periasamy M, et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res. 1993;73:1000–1012.

Garanci JS, Mathura RA, Shi ZD, Tarbell JM. Effects of fluid shear stress on adventitial fibroblast migration; implications for flow-mediated mechanisms of arteriolarization and intimal hyperplasia. Am J Physiol Heart Circ Physiol. 2007;292:H3128–H3135.

Madsen CS, Regan CP, Hungerford JE, White SL, Manabe I, Owens GK. Smooth muscle-specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires S-flanking and first intronic DNA sequence. Circ Res. 1999;82:908–917.

Liu R, Jin JP. Calponin isoforms CNN1, CNN2 and CNN3: regulators for actin cytoskeleton functions in smooth muscle and non-muscle cells. Gene. 2016;585:143–153.

Miano JM, Olson EN. Expression of the smooth muscle cell calponin gene marks the early cardiac and smooth muscle cell lineages during mouse embryogenesis. J Biol Chem. 1996;271:7095–7103.

Frid MG, Shekhonin BV, Kotelsiansky VE, Glukhova MA. Phenotypic changes of human smooth muscle cells during development: late expression of heavy caldesmon and calponin. Dev Biol. 1992;153:185–193.

Perez-Montiel MD, Plaza JA, Dominguez-Malagon H, Suster S. Differential expression of smooth muscle myosin, smooth muscle actin, H-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue. Am J Dermatopathol. 2009;31:394–401.

Hu WY, Fukuda N, Ikeda Y, Suzuki R, Tahira Y, Takagi H, Matsumoto K, Kamatsukue K, Mugishima H. Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype. J Cell Physiol. 2003;196:284–292.

Khwang BA, Cearns I, Pien PL, Narula J. Radionuclide imaging of the synthetic smooth muscle cell phenotype in experimental atherosclerotic lesions. Trends Cardiovasc Med. 1998;6:226–232.

Kudryavtseva O, Aalkjaer C, Matchkov VV. Vascular smooth muscle cell phenotype is defined by Ca2+-dependent transcription factors. FEBs J. 2013;280:5488–5499.

Karbor V, Fini MA, Loomis Z, Sullivan T, Hersh LB, Gerasimovskaya E, Irwin D, Dempsey EC. Sustained activation of Rho GTPases promotes a synthetic pulmonary artery smooth muscle cell phenotype in neonatal rat pulmonary artery smooth muscle cells. Am J Physiol Heart Circ Physiol. 2003;285:H1444–H1452.

Zhong L, He X, Si X, Wang H, Li B, Hu Y, Li M, Chen X, Liao W, Liao Y, et al. SM22α (smooth muscle 22α) prevents aortic aneurysm formation by inhibiting smooth muscle cell phenotypic switching through suppressing reactive oxygen species/NF-κB (nuclear factor-κB) expression in vascular smooth muscle cells. Circ Res. 2004;94:101–111.

Van Eys G, Niessen P, Remsen S. Smoothelin in vascular smooth muscle cells. J Biol Chem. 2004;279:28400–28407.

Herring BP, El-Mounayri Q, Gallagher PJ, Yin F, Zhou J. Regulation of myosin light chain kinase and telokin expression in smooth muscle tissues. Am J Physiol Cell Physiol. 2006;291:C817–C827.

Schaller MD. Paxillin: a focal adhesion-associated adapter protein. Oncogene. 2001;20:6459–6472.

Yumimamochi T, Yatomi Y, Osada M, Omori T, Ishii Y, Nakazawa K, Hosogaya S, Ozaki Y. Expression of the LIM proteins paxillin and Hic-5 in human tissues. J Histocherm Cytochem. 2003;51:513–521.

Peng X, Nelson ES, Maisel JL, DeMali KA. New insights into vinculin function and regulation. Int Rev Cell Mol Biol. 2011;287:191–231.

Belkin AM, Ormatsky OL, Kabakov AE, Glukhova MA, Kotelsiansky VE. Diversity of vinculin/met vinculin in human tissues and cultured cells: expression of muscle specific variants of vinculin in human aorta smooth muscle cells. J Biol Chem. 1998;263:8631–8635.

Chen D, Ma L, Tham EL, Maresh S, Lechler RI, McVey JH, Dorling A. Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms. J Thromb Haemost. 2013;11:963–974.

Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoacic activation of adventitial fibroblasts: role in vascular remodeling. Chest. 2002;122:3265–3272.

Imoto K, Okada M, Yamawaki H. Characterization of fibroblasts from hypertrophied right ventricle of pulmonary hypertensive rats. Pflugers Arch. 2018;470:1405–1417.

Rodriguez A, Karen J, Gardner H, Gerdin B, Rubin K, Sundberg C. Integrin alpha5beta1 is involved in the differentiation into myofibroblasts from human foreskin fibroblasts. J Cell Mol Med. 2009;13:3449–3462.

Messier RH Jr, Bass BL, Aly HM, Jones JL, Domkowski PW, Wallace RB, Hopkins RA. Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res. 1994;57:1–21.

Jin X, Fu GX, Li XD, Zhu DL, Gao PJ. Expression and function of osteopontin in vascular adventitial fibroblasts and pathological vascular remodeling. PLoS One. 2011;6:e23585.

Kudryavtseva O, Aalkjaer C, Matchkov VV. Vascular smooth muscle cell phenotype is defined by Ca2+-dependent transcription factors. FEBs J. 2013;280:5488–5499.

Pavoni F, De Marco F, Morselli PL, Ghermanis C, Dall’Era F, Iannicelli S, Castagna R, Spaggiari O, Uccellini R, Petrucci M, et al. The role of the fibroblast growth factor 21 (FGF21) signaling pathway in the regulation of hepatic regenerative processes. Hepatology. 2017;66:1877–1889.

Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoacic activation of adventitial fibroblasts: role in vascular remodeling. Chest. 2002;122:3265–3272.

Imoto K, Okada M, Yamawaki H. Characterization of fibroblasts from hypertrophied right ventricle of pulmonary hypertensive rats. Pflugers Arch. 2018;470:1405–1417.

Rodriguez A, Karen J, Gardner H, Gerdin B, Rubin K, Sundberg C. Integrin alpha5beta1 is involved in the differentiation into myofibroblasts from human foreskin fibroblasts. J Cell Mol Med. 2009;13:3449–3462.

Messier RH Jr, Bass BL, Aly HM, Jones JL, Domkowski PW, Wallace RB, Hopkins RA. Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res. 1994;57:1–21.

Khwang BA, Cearns I, Pien PL, Narula J. Radionuclide imaging of the synthetic smooth muscle cell phenotype in experimental atherosclerotic lesions. Trends Cardiovasc Med. 1998;6:226–232.

Kudryavtseva O, Aalkjaer C, Matchkov VV. Vascular smooth muscle cell phenotype is defined by Ca2+-dependent transcription factors. FEBs J. 2013;280:5488–5499.

Pavoni F, De Marco F, Morselli PL, Ghermanis C, Dall’Era F, Iannicelli S, Castagna R, Spaggiari O, Uccellini R, Petrucci M, et al. The role of the fibroblast growth factor 21 (FGF21) signaling pathway in the regulation of hepatic regenerative processes. Hepatology. 2017;66:1877–1889.

Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoacic activation of adventitial fibroblasts: role in vascular remodeling. Chest. 2002;122:3265–3272.
Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res. 2018;114:540–550.

Orr AW, Hastings NE, Blackman BR, Wamhoff BR. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res. 2010;47:188–180.

Chung SW, Park JW, Lee SA, Eo SK, Kim K. Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell. Biochem Biophys Res Commun. 2010;396:748–754.

Kwansa AL, De Vita R, Freeman JW. Tensile mechanical properties of collagen type I and its enzymatic crosslinks. Biophys Chem. 2016;214:215–10.

Nadkarni SK, Bouma BE, de Boer J, Teamey GJ. Evaluation of collagen in atherosclerotic plaques: the use of two coherent laser-based imaging methods. Lasers Med Sci. 2009;24:439–445.

Rekhter MD. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res. 1999;41:376–384.

Franz T, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123:4196–4200.

Liu X, Huang X, Chen L, Zhang Y, Li M, Wang L, Ge C, Wang H, Zhang M. Mechanical stretch promotes matrix metalloproteinase-2 and prolyl-4-hydroxylase α1 production in human aortic smooth muscle cells via Akt-p38 MAPK-JNK signaling. Int J Biochem Cell Biol. 2015;62:15–23.

Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3:311–322.

Joo D, Zhang L, Liu T. Mechanistic insights into matrix metalloproteinase expression and the role of osteopontin in human vascular smooth muscle cells. J Cell Biol. 2015;159:17–24.

Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115:3861–3863.

Hamill KJ, Kligs K, Hopkinson SB, Jones JC. Laminin deposition in the extracellular matrix: a complex picture emerges. J Cell Sci. 2009;122:4409–4417.

Hallmann R, Horn N, Seig M, Wendler O, Pausch F, Sorokin LM. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;58:17–24.

Kim HW, Weintraub NL. Aortic aneurysm: in defense of the vascular smooth muscle cell. Arterioscler Thromb Vasc Biol. 2016;36:2138–2140.

Doderer SA, Gabel G, Kojke VBC, Northoff BH, Holldt LM, Hamming JF, Lindeboom JHN. Adventitial adipogenic degeneration is an unidentified contributor to aortic wall weakening in the abdominal aortic aneurysm. J Vasc Surg. 2018;67:1891–1900.

Van der Velde AR, Meijers WC, de Boer RA. Cardiovascular biology or atheroprotective? Trends Cardiovasc Med. 2017;12:14–23.

Lasers Med Sci. 2019;34:1280–1289.

Clin Sci (Lond). 2009;115:3861–3863.

Arterioscler Thromb Vasc Biol. 2015;34:724–736.

J Thorac Cardiovasc Surg. 2018;156:1863–1870.

Nat Commun. 2019;10:11853.

Casuarina Physiol. 2005;65:979–1000.

J Cell Biol. 2002;82:619–628.

J Biol Chem. 1999;41:376–384.

Arterioscler Thromb Vasc Biol. 2014;34:724–736.

Lasers Med Sci. 2013;112:17–22.

J Cell Biol. 1997;272:6332–6340.

Nat Rev Immunol. 2015;15:644–457.

J Cell Biol. 2008;182:1697–1703.

Arterioscler Thromb Vasc Biol. 2015;35:839–851.

Expert Rev Cardiovasc Ther. 2018;16:444–457.

J Am Heart Assoc. 2016;5:e006798. DOI: 10.1161/JAHA.116.006798.

Cell Biochem. 2014;15:802–812.

J Cell Biol. 2018;115:662–667.

Nat Rev Mol Cell Biol. 2014;15:802–812.

Arterioscler Thromb Vasc Biol. 2008;28:812–819.

J Cell Sci. 2018;131:839–851.

Nat Commun. 2019;10:147–152.
153. von Essen M, Rahikainen R, Oksala N, et al. Talin and vinculin are downregulated in atherosclerotic plaque. Tampere Vascular Study. Atherosclerosis. 2016;254:53–63.

154. van Dijk RA, Rijs K, Wezel A, Hamming JF, Kolodziej FD, Virmanni R, Schaapherder AF, Lindeman JHN. Systematic evaluation of the cellular innate immune response during the process of human atherosclerosis. J Am Heart Assoc. 2016;5:e002860. DOI: 10.1161/JAHA.115.002860.

155. van Dijk RA, Dunisveld AJ, Schaapherder AF, Mulder-Stapel A, Hamming JF, Kuper J, de Boer OJ, van der Wal AC, Kolodziej FD, Virmanni R, et al. A change in inflammatory footprint precedes plaque instability: a systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis. J Am Heart Assoc. 2015;4:e001403. DOI: 10.1161/JAHA.114.001403.

156. Moher D, Leiter L, Clarke M, Gheusi M, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

157. Majesky MW, Horita H, Ostriker A, Lu S, Regan JN, Bagchi A, Dong XR, Poczobutt J, Nemenoff RA, Weiser-Evans MC. Differentiated smooth muscle and myofibroblast differentiation in mesenchymal stromal cells in the microenvironment of the IPF lung. J Clin Investig. 2017;127:93652.

158. Sava P, Ramanathan A, Dobronyi A, Peng X, Sun H, Ledesma-Mendoza A, Herzog EL, Gonzalez AL. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung. J Clin Investig. 2017;127:93652.

159. Zheng L, Xu CC, Chen WD, Shen WL, Zhu LM, Zhu DL, Gao PJ. MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun. 2010;400:483–488.

160. Ji J, Xu F, Li L, Chen R, Wang J, Hu WC. Activation of adventitial fibroblasts in the early stage of the aortic transplant vasculopathy in rat. Transplantation. 2010;89:945–953.

161. Gan Q, Yoshida T, Li J, Owens GK. Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res. 2007;101:883–892.

162. Guo SJ, Wu LY, Shen WL, Chen WD, Wei J, Gao PJ, Zhu DL. Gene profile for differentiation of vascular adventitial myofibroblasts. Sheng Li Xue Bao. 2006;58:337–344.

163. Butcher JT, Barrett BC, Nerem RM. Equatorial strain stimulates fibroblastic phenotype shift in smooth muscle cells in an engineered tissue model of the aortic wall. Biomaterials. 2006;27:5252–5258.

164. Jiang YL, Dai AG, Li QF, Hu RC. Transforming growth factor-beta1 induced fibroblasts transdifferentiation of fibroblasts into myofibroblasts in hypoxic pulmonary vascular remodeling. Acta Biochim Biophys Sin (Shanghai). 2006;38:29–36.

165. Miyazaki H, Hayashi K, Hasegawa Y. Tensile properties of fibroblasts and vascular smooth muscle cells. Biochemistry. 2005;40:207–212.

166. Das M, Dempsey EC, Reyes JT, Stemran KR. Selective expansion of fibroblast subpopulations from pulmonary artery adventitia in response to hypoxia. Am J Physiol Lung Cell Mol Physiol. 2002;282:L876–L886.

167. Zhong A, Mirzaei Z, Simmons CA. The roles of matrix stiffness and β-catenin signaling in endothelial-to-mesenchymal transition of aortic valve endothelial cells. Cardiovasc Eng Technol. 2018;9:158–167.

168. Zhang L, Chen Y, Li G, Chen M, Huang W, Liu Y, Li Y. TGF-β1 signaling mediates the 15-HETE-induced differentiation of adventitial fibroblasts into myofibroblasts in aortic transplant vasculopathy. Lipids Heart Dis. 2019;18:1002.

169. Castellano G, Franzin R, Stasi A, Divella C, Sallustio F, Pontrelli P, Lucarelli G, Battaglia M, Staffieri F, Crovace A, et al. Complement activation during ischemia/reperfusion injury induces pericyte-to-myofibroblast transdifferentiation regulating peritubular capillary lumen reduction through ePERK signaling. Front Immunol. 2018;9:1002.

170. Chen C, Han X, Fan F, Liu Y, Wang T, Wang J, Hu P, Ma A, Tian H. Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1-Smad3-mediated fibrotic responses through 5-HT2A receptors. Mol Cell Biol. 2014;34:267–276.

171. Lin S, Ma S, Lu P, Cai W, Chen Y, Sheng J. Effect of CTRP3 on activation of adventitial fibroblasts induced by TGF-β1 from rat aorta in vitro. Int J Clin Exp Pathol. 2014;7:2199–2208.

172. Okayama K, Azuma J, Dosaka K, Ikekchi K, Sanada F, Kusunoki H, Iwabayashi M, Rakugi H, Taniyama Y, Morishita R. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension. 2012;59:958–965.

173. Wang Y, Zhang J, Wang H, Gao P, Singh M, Shen K, Fang N. Angiotensin II downregulates catalase expression and activity in vascular adventitial fibroblasts through an AT1R/ERK1/2-dependent pathway. Mol Cell Biol. 2011;31:2150–2159.

174. Das M, Dempsey EC, Reyes JT, Stemran KR. Selective expansion of fibroblast subpopulations from pulmonary artery adventitia in response to hypoxia. Am J Physiol Lung Cell Mol Physiol. 2002;282:L876–L886.

175. Forte A, Della Corte A, Grossi M, Barcone C, Provenzano R, Finicelli M, De Feo M, De Santo LS, Nappi G, Cotrufo M, et al. Early cell phenotype control in vascular adventitial fibroblasts. J Cell Biol. 2010;400:483–488.

176. Cushing MC, Mariner PD, Liao JT, Sims EA, Anseth KS. Fibroblast to myofibroblast differentiation in response to TGF-β1 and bFGF mediates angiogenesis. J Cell Biochem. 2009;105:158–167.

177. Miyazaki H, Hayashi K, Hasegawa Y. Tensile properties of fibroblasts and vascular smooth muscle cells. Biochemistry. 2005;40:207–212.

178. Jiang YL, Dai AG, Li QF, Hu RC. Transforming growth factor-beta1 induced fibroblasts transdifferentiation of fibroblasts into myofibroblasts in hypoxic pulmonary vascular remodeling. Acta Biochim Biophys Sin (Shanghai). 2006;38:29–36.
cooperate with vasa vasorum endothelial cells to regulate vasa vaso-
rum neovascularization; a process mediated by hypoxia and endothe-
lin-1. Am J Pathol. 2006;168:1793–1807.

194. Tomas JJ, Stark VE, Kim JL, Woff PF, Hullett DA, Warner TF, Hoch
JR. Beta-galactosidase-tagged adventitial myofibroblasts tracked to
the neointima in healing rat vein grafts. J Vasc Res. 2003;40:266–275.

195. Siow RC, Mallawarachchi CM, Weissberg PL. Migration of adventitial
myofibroblasts following vascular balloon injury: insights from in vivo
gene transfer to rat carotid arteries. Cardiovasc Res. 2003;59:212–221.

196. Frid MG, Vala VA, Stenmark KR. Mature vascular endothelium can
give rise to smooth muscle cells via endothelium-mesenchymal trans-
derivation; in vivo analysis. Circ Res. 2002;90:1189–1196.

197. Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, Metz CN.
Fibrocytes induce an angiogenic phenotype in cultured endothelial
cells and promote angiogenesis in vivo. FASEB J. 2001;15:2215–2224.

198. Hirose M, Kosugi H, Nakazato K, Hayashi T. Restoration to a quiescent
phenotype of adventitial myofibroblasts following vascular balloon injury: a review of the evidence and future
directions. Trends Cardiovasc Med. 2019;29:61–68.

199. Shi Y, O’Brien JE Jr, Fard A, Zalewski A. Transforming growth fac-
tor-beta 1 expression and myofibroblast formation during arterial re-
pair. Arterioscler Thromb Vasc Biol. 1996;16:1298–1305.

200. Shi Y, O’Brien JE Jr, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial
myofibroblasts contribute to neointimal formation in injured porcine
coronary arteries. Circulation. 1996;94:1655–1664.

201. Zhang YG, Li J, Li YG, Wei RH. Urotensin II induces phenotypic differ-
entiation, migration, and collagen synthesis of adventitial fibroblasts
from rat aorta. J Hypertens. 2008;26:1119–1126.

202. Patel S, Shi Y, Niculescu R, Chung EH, Martin JL, Zalewski A.
Characteristics of coronary smooth muscle cells and adventitial fibro-
blasts. Circulation. 2000;101:524–532.

203. Frösen J, Joutel A. Smooth muscle cells of intracranial vessels: from
morphology and phenotype for functional tissue-engineered small-di-
meter blood vessels. Cell Mol Neurobiol. 2011;31:2370–2377.

204. Majesky MW. Vascular smooth muscle cells. Circ Res. 2015;26:1119–1126.

205. Yuan SM. Characterization of coronary smooth muscle cells and adventitial fibro-
blast-like human aortic smooth muscle cells by culture on type IV col-
lagen gels. J Biochem. 1999;125:991–1000.

206. Archer SL. Diversity of phenotype and function of vascular smooth
muscle cells. J Lab Clin Med. 1996;127:524–529.

207. Thyberg J. Differentiated properties and proliferation of arterial smooth
muscle cells in culture. Int Rev Cytol. 1996;168:183–265.

208. Sarmento S, Scatena M, Chavagot A, Faggion E, Giuriato L, Palouett P.
Myosin isoform expression in smooth muscle cells during physiologi-
cal and pathological vascular remodeling. J Vasc Res. 1994;31:61–81.

209. Harrison OJ, Visan AC, Moorjani N, Modi A, Salihyeh K, Torrens C,
Ohri S, Cagampang FR. Defective NOTCH signaling drives increased
vascular smooth muscle cell apoptosis and contractile differentiation
in a murine model of atherosclerotic plaque. Cell Death Disc. 2018;25:374–379.

210. Sun QR, Zhang X, Fang K. Phenotype of vascular smooth muscle cells
(VSMCs) is regulated by mTOR by testing sirtuin 1. Med Sci Monit.
2018;24:6599–6607.

211. Zhang M, Luo Y, C Li R, Chen N, Deng F, Wang D, Luo W, Wu, J,
Luo M. Platelet-endothelial cell interactions modulate smooth muscle cell
phenotype in an in vitro model of type 2 diabetes mellitus. Am J Physiol Cell Physiol. 2019;316:C186–C197.

212. Yi B, Shen Y, Tang H, Wang X, Li B, Zhang Y. Stiffness of aligned fibers
regulates the phenotypic expression of vascular smooth muscle cells.
ACS Appl Mater Interfaces. 2019;11:8687–8690.

213. Wu W, Zhang W, Choi M, Zhao J, Gao P, Xue M, Senior HA, Jourdheul
Dong X. Vascular smooth muscle-MAPK1 is required for neointimal
hyperplasia by suppressing VSMC differentiation and inducing prolif-
eration and inflammation. Redox Biol. 2019;22:101137.

214. Misra RC, Wagh D, Paik DT, Pajar M, Nguyen T, Miller CL, Kundu R,
Nagao M, Coller J, Koyano TK, et al. Atheroprotective roles of smooth
muscle cell phenotypic modulation and the TCF21 disease gene as
regulated in atherosclerotic calcification and affects vascular smooth
muscle cell phenotype. Genet Med. 2019;51:1580–1587.

215. Sun L, Zhao M, Liu A, Lu M, Zhang J, Li Y, Yang X, Wu Z. Shear stress
induces phenotypic modulation of vascular smooth muscle cells via
AMPK/mTORULK1-mediated autophagy. Cell Mol Neurobiol. 2018;38:541–548.

216. Wu B, Zhang L, Zhu YH, Wang YE, Zheng F, Yang JY, Guo LY, Li XY,
Wang L, Tang JM, et al. Mesoderm/mesenchyme homeobox gene I
promotes vascular smooth muscle cell phenotypic modulation and
vascular remodeling. J Int J Cardiol. 2018;251:82–89.

217. Fu Y, Chang Y, Chen S, Li Y, Chen Y, Sun G, Yu S, Ye N, Li C,
Sun Y. BAG3 promotes the phenotypic transformation of pri-
mary rat vascular smooth muscle cells via TRAIL. Int J Mol Med.
2018;41:2917–2926.

218. Charles R, Bour moum M, Claing A, ARF GTPases control phenotypic
switching to vascular smooth muscle cells through the regulation of
actin function and actin dependent gene expression. Cell Signal.
2018;48:64–74.

219. Frid MG, Dempsey EC, Durnmowicz AG, Stenmark KR. Smooth muscle
cell heterogeneity in pulmonary and systemic vessels: importance in
vascular disease. Arterioscler Thromb Vasc Biol. 1997;17:1203–1209.

220. Archer SL. Diversity of phenotype and function of vascular smooth
muscle cells. J Lab Clin Med. 1996;127:524–529.

221. Thyberg J. Differentiated properties and proliferation of arterial smooth
muscle cells in culture. Int Rev Cytol. 1996;168:183–265.
240. Mirsa A, Feng Z, Chandran RR, Kabir I, Rotlani N, Aryan B, Sheikh AQ, Ding L, Qin L, Fernández-Hernando C, et al. Integrin beta1 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells. Nat Commun. 2018;9:2073.

241. Smyth LCD, Rustenhoven J, Scotter EL, Schwedler F, Faull RL, Park NJ. Up-regulation of connexin43 correlates with increased synthetic activity and enhanced contractile differentiation in TGF-beta-treated human aortic smooth muscle cells. Eur J Cell Biol. 2006;85:375–386.

242. Acampora KB, Nagatomi J, Langan EM III, LaBerge M. Increased synthetic phenotype behavior of smooth muscle cells in response to in vitro balloon angioplasty injury model. Ann Vasc Surg. 2010;24:116–126.

243. Augstein A, Mar JE, Poitz DM, Strasser RH. Sox9 is increased in arterial plaque and stenosis, associated with synthetic phenotype of vascular smooth muscle cells and causes alterations in extracel- lular matrix and calcification. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2526–2537.

244. Alshawan AR, Riches-Suman K, O'Regan DJ, Wood IC, Turner NA, Porter KE. MicroRNA-21 drives the switch to a synthetic phe- notype in human sepsis vein smooth muscle cells. IUBMB Life. 2018;70:649–657.

245. Thyberg J, Blomgren K, Roy J, Tran PK, Hedin U. Phenotypic mod- ulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J Histochm Cytochem. 1997;45:837–846.

246. Thyberg J, Hultgård-Nilsson A. Fibronectin and the basement membrane components laminin and collagen type IV influence the phenotypic properties of subcultured rat aortic smooth muscle cells differently. Cell Tissue Res. 1994;276:263–271.

247. Anwar A, Li M, Frid MG, Kumar B, Gerasimovskaya EV, Riddle SR, McKeon BA, Thukaram R, Meyrick BO, Fini MA, et al. Osteopontin is an endogenous modulator of the constitutively activated phenotype of proangiogenic adventitial fibroblasts in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2012;303:L11–L11.

248. Giachelli C, Bae N, Lombardi D, Majesky M, Schwartz S. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein 1, 2αR). Biochem Biophys Res Commun. 1991;177:687–673.

249. Okada Y, Katsuda S, Matsuji Y, Watanabe H, Nakashima I. Collagen synthesis by cultured arterial smooth muscle cells during spontaneous phenotypic modulation. Acta Pathol Jpn. 1990;40:157–164.

250. Ang AH, Tachas G, Campbell JH, Bateman JF, Campbell GR. Collagen synthesis by cultured rabbit aortic smooth muscle cells: alteration with phenotypic. Biochem J. 1990;265:461–469.

251. Chiarii A, Onorati F, Marconi M, Pasquali A, Patuzzo C, Malashicheva A, Irytgea G, Faggian G, Pignatti PF, Trabetti E, et al. Studies on sporadic non-syndromic thoracic aortic aneurysms: 1: deregulation of Jagged/Notch 1 homeostasis and selection of synthetic/secretor phe- notype smooth muscle cells. Eur J Prev Cardiol. 2018;25:42–50.

252. Denger S, Jahn L, Wende P, Watson L, Gerber SH, Kübler W, Kreuzer J. Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: induction of the synthetic phenotype: a model for arteriosclerosis. J Cell Biol. 1990;40:157–164.

253. Ghoshray S, Kollar B, Nahar T, Suresh Babu S, Wojtowicz A, Sticht C, Gretz N, Wagner AH, Kortt T, Hecker M. Loss of the mechanotrans- ducer zyxin promotes a synthetic phenotype of vascular smooth muscle cells. J Am Heart Assoc. 2015;4:e001712. DOI: 10.1161/ JAHAA.114.001712.

254. Lee HS, Yun SJ, Ha JM, Sin HY, Yang YC, Liao YC, Joo SH. microRNA let-7g suppresses PDGF-induced conversion of vascular smooth muscle cell into the synthetic phenotype. J Cell Mol Med. 2017;21:3592–3601.

255. Pakh K, Jong L, Jung SM, Young H, Yong Park J, Woo Byun J, Lee YS, Chul Paeng J, Kim C, Kim S, et al. Visualization of synthetic vascular smooth muscle cells in atherosclerotic carotid artery with F-18 FDG PET. Sci Rep. 2017;7:6989.

256. Ghosh S, Kollar B, Nahar T, Suresh Babu S, Wojtowicz A, Sticht C, Gretz N, Wagner AH, Kortt T, Hecker M. Loss of the mechanotrans- ducer zyxin promotes a synthetic phenotype of vascular smooth muscle cells. J Am Heart Assoc. 2015;4:e001712. DOI: 10.1161/ JAHAA.114.001712.

257. Lee HS, Yun SJ, Ha JM, Sin HY, Hong SH, Kim CD, Bae SS. Prostaglandin D2 stimulates phenotypic changes in vascular smooth muscle cells. Exp Mol Med. 2019;51:10–11.

258. Jamison A, Reesink K, Kroon A, Schurgers L. The role of vascular smooth muscle cells in arterial remodeling: focus on calcification-re- lated processes. Int J Mol Sci. 2019;20:5684.

259. Clement M, Chappell J, Raffort J, Lareyre F, Vandenstee M, Taylor AL, Finigan A, Harrison J, Bennett MR, Bruneval P, et al. Vascular smooth muscle cell plasticity and autophagy in dissecting aortic aneu- ryms. Arterioscler Thromb Vasc Biol. 2019;39:1149–1159.

260. Owens GK, Pasterkamp G, PiajoMics Leducq Foundation Trans- Atlantic Network: defining the roles of smooth muscle cells and other
extracellular matrix-producing cells in late-stage atherosclerotic plaque pathogenesis. Circ Res. 2019;124:1297–1299.

276. Liu M, Gomez D. Smooth muscle cell phenotypic diversity. Arterioscler 297. Thesis Vasc Biol. 2019;39:1715–1723.

277. Yuan SM, Wu N. Aortic alpha-smooth muscle actin expressions in aortic disorders and coronary artery disease: an immunohistochemical study. Anatol J Cardiol. 2018;19:11–16.

278. Lin CS, Hsieh PS, Hwang LL, Lee YH, Tsai SH, Tu YC, Hung YW, Choi S, Park M, Kim J, Park W, Kim S, Lee DK, Hwang JY, Choe J, Banks MF, Gerasimovskaya EV, Tucker DA, Frid MG, Carpenter TC, Schwartz SM, Virmani R, Majesky MW. An update on clonality: Zhong L, He X, Si X, Wang H, Li B, Hu Y, Li M, Chen X, Liao W, Liao Yuan SM, Wu N. Aortic alpha-smooth muscle actin expressions in aortic disorders and coronary artery disease: an immunohistochemical study. Anatol J Cardiol. 2018;19:11–16.

279. 2018;3:e0196628.

280. Foster LC, Arkanac BM, Siblinga NES, Shi C, Perrella MA, Haber E. Regulation of CD44 gene expression by the proinflammatory cytokine interleukin-1beta in vascular smooth muscle cells. J Biol Chem. 1998;273:20341–20346.

281. Clement N, Gueguen M, Glorian M, Blaise R, Andreani M, Brou C, Bausero P, Limon I. Notch3 and IL-1beta exert opposing effects on a vascular smooth muscle cell inflammatory pathway in which NF-kappaB drives crosstalk. J Cell Sci. 2007;120:3352–3361.

282. Schwartz SM, Vrman R, Majesky MW. An update on clonality: what smooth muscle cell type makes up the atherosclerotic plaque? F1000Res. 2018;7:F1000 Faculty Rev-1969.

283. Rensing SSM, Doevendans PAFM, Van Eys GJJM. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;15:100–108.

284. Mahoney WM Jr, Schwartz SM. Defining smooth muscle cells and smooth muscle injury. J Clin Invest. 2005;115:221–224.

285. Li J, Zhang YQ, Luo LM, Dong X, Ding WH, Dang SY. Urotensin II promotes aldosterone expression in rat aortic adventitial fibroblasts. Mol Med Rep. 2018;17:2921–2928.

286. Yin L, Cai W, Sheng J, Sun Y. Hypoxia induced changes of SelP1 expression in rat aortic adventitia and its impact on vascular fibroblasts. Int J Clin Exp Med. 2014;7:41–50.

287. Brittan M, Chance V, Elia G, Poulsom R, Alison MR, MacDonald TT, Wright NA. A regenerative role for bone marrow following experimental colitis: contribution to neovascularogenesis and myofibroblasts. Gastroenterology. 2005;128:1984–1995.

288. Banks MF, Gerasimovskaya EV, Tucker DA, Frid MG, Carpenter TC, Stenmark KR. Egr-1 antisense oligonucleotides inhibit hypoxia-induced proliferation of pulmonary artery adventitial fibroblasts. J Appl Physiol (1985). 2005;98:732–738.

289. Gerasimovskaya EV, Tucker DA, Stenmark KR. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation. J Appl Physiol (1985). 2005;98:722–731.

290. Das M, Stenmark KR, Dempsey EC. Enhanced growth of fetal and neonatal pulmonary artery adventitial fibroblasts is dependent on protein kinase C. Am J Physiol Lung Cell Mol Physiol. 1995;269:L660–L667.

291. Moultou KS, Li M, Strand K, Burgett S, McClatchey P, Tucker R, Furgesby SB, Lu S, Kirkpatrick B, Cleveland JC, et al. P38 mitogen activation promotes pathological vascular remodeling of human coronary arteries. JCI Insight. 2018;3:e97228.

292. Wesseling M, Sakkers TR, de Jager SC, Pasterkamp G, Goumans MJ. The morphological and molecular mechanisms of epithelial/endothelial-to-mesenchymal transition and its involvement in arteriosclerosis. Vaspar Pharmacol. 2018;106:1–9.

293. Kim M, Choi SH, Jin YB, Lee HJ, Ji YH, Kim J, Lee YS, Lee YJ. The effect of oxidized low-density lipoprotein (ox-LDL) on radiation-induced endothelial-to-mesenchymal transition. Int J Radiat Biol. 2013;89:356–363.

294. Tang R, Li Q, Lv L, Dai H, Zheng M, Ma K, Liu B. Angiogenesis II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells. Cardiov Vasch Pharmacol. 2019;39:1715–1723.
SUPPLEMENTAL MATERIAL
Data S1. Systematic Search Protocol for most commonly used phenotypical and functional mesenchymal markers in the vascular research field\textsuperscript{160,161}

Administrative information

Authors- contact and contributions:

1. J.H. Lindeman. Dept. of Surgery, Division of Vascular Surgery, Leiden University Medical Center. J.H.N.Lindeman@lumc.nl

2. L.E. Bruijn: Dept. of Surgery, Division of Vascular Surgery, Leiden University Medical Center. L.E.Bruijn@lumc.nl

Contributions:
Both authors reviewed the titles, abstracts and full-texts for eligibility independently, based on the search strategy developed by author L.E. Bruijn in collaboration with search specialist J.W. Schoones, LUMC.

Financial support: none

Methods

Information sources: Pubmed and Embase

Pubmed search strategy:

\(("Phenotype"[mesh:noexp] OR phenotyp*[tiab] OR "phenotypic modulation"[tw] OR "phenotypic regulation"[tw] OR "phenotypic differentiation"[tw] OR "phenotypic characterization"[tw] OR "phenotypic characterisation"[tw] OR "phenotypic diversity"[tw] OR "phenotypic heterogeneity"[tw] OR phenotypic modulat*[tw] OR
phenotypic regulat*[tw] OR phenotypic different*[tw] OR phenotypic character*[tw] OR phenotypic divers*[tw] OR phenotypic heterog*[tw] OR (“phenotypic*[ti] OR "pheno*[ti] AND (“modulation*[ti] OR “regulation*[ti] OR “differentiation*[ti] OR “characterization*[ti] OR “characterisation*[ti] OR “diversity*[ti] OR “heterogeneity*[ti]) OR “vascular remodeling*[tw] OR “vascular remodelling*[tw]) AND (“Fibroblasts*[majr] OR “Myofibroblasts*[majr] OR “fibroblast*[ti] OR “fibroblasts*[ti] OR fibroblast*[ti] OR “myofibroblast*[ti] OR “myofibroblasts*[ti] OR myofibroblast*[ti] OR “Myocytes, Smooth Muscle*[majr] OR “smooth muscle cell*[ti] OR “smooth muscle cells*[ti]) AND (“Blood Vessels*[majr] OR “blood vessels*[ti] OR “blood vessel*[ti] OR “artery*[ti] OR “arteries*[ti] OR “aorta*[ti] OR “aortic*[ti] OR “Arteriosclerosis*[majr] OR “Atherosclerosis*[majr] OR atherosclero*[ti] OR arteriosclero*[ti] OR “coronary artery disease*[ti] OR “coronary artery diseases*[ti] OR “AAA*[ti] OR “Aortic Aneurysm, Abdominal*[majr] OR “Abdominal Aortic Aneurysm*[ti] OR “Abdominal Aortic Aneurysms*[ti]) NOT (“mesenchymal stem cells*[ti] OR “mesenchymal stem cell*[ti] OR “Mesenchymal Stromal Cells*[Majr]) AND (“1990/01/01*[PDAT] : “3000/12/31*[PDAT]) AND (english[la] OR dutch[la])

Total number of references: 2698

Date: 9-12-2019
Data S2. Embase search strategy.

('Phenotype'/ OR Phenotyp*.ti,ab. OR 'Phenotypic modulation.mp. OR 'Phenotypic regulation'.mp. OR 'Phenotypic differentiation'.mp. OR 'Phenotypic characterization'.mp. OR 'Phenotypic characterisation'.mp. OR 'Phenotypic diversity'.mp. OR 'Phenotypic heterogeneity'.mp. OR Phenotypic modulat*.mp. OR Phenotypic regulat*.mp. OR Phenotypic different*.mp. OR Phenotypic character*.mp. OR Phenotypic divers*.mp. OR Phenotypic heterog*.mp. OR (('Phenotypic'.ti. OR 'Pheno'.ti.) AND ('Modulation'.ti. OR 'Regulation'.ti. OR 'Differentiation'.ti. OR 'Characterization'.ti. OR 'Characterisation'.ti. OR 'Diversity'.ti. OR 'Heterogeneity'.ti.)) OR 'Vascular Remodeling'.mp. OR 'Vascular Remodelling'.mp.) AND ('Fibroblasts'/ OR 'Myofibroblasts'/ OR 'Smooth Muscle cell'/ OR 'Fibroblast'.ti. OR 'Fibroblasts'.ti. OR Fibroblast*.ti. OR 'Myofibroblast'.ti. OR 'Myofibroblasts'.ti. OR Myofibroblast*.ti. OR 'Smooth muscle cell'.ti. OR 'Smooth muscle cells'.ti.) AND ('Blood Vessels'/ OR 'Arteriosclerosis'/ OR 'Atherosclerosis'/ OR 'Abdominal aortic aneurysm'/ OR 'Blood vessels'.ti. OR 'Blood vessel'.ti. OR 'artery'.ti. OR 'Arteries'.ti. OR 'Aorta'.ti. OR 'Aortic'.ti. OR 'Atherosclero'.ti. OR Arteriosclero*.ti. OR 'Arteries'.ti. OR 'Aorta'.ti. OR 'Aortic'.ti. OR 'Atherosclerosis'.ti. OR 'AAA'.ti. OR 'Abdominal Aortic Aneurysm'.ti. OR 'Abdominal Aortic Aneurysms'.ti.) NOT 'Mesenchymal stroma cell'/ OR 'Mesenchymal stem cell'.ti. OR 'Mesenchymal stem cells'.ti.

Total number of references: 1371

Date: 10-12-2019
**Data management:** References were stored in a PDF-file.

**Selection and data collection process:** author L.E. Bruijn retrieved all included articles on 09-12-2019 in Pubmed and Embase with the search strategy. Gray literature was not located for this study. Next, the two reviewers independently undertook the initial selection based upon title, abstract and keywords. In case of disagreement, the two reviewers discussed whether the study should be included or excluded based on the initial selection. Subsequently, full texts were reviewed when eligibility was considered either definite or ambiguous.

**Outcomes and prioritization:**

Potential relevant differentiation/functional markers were extracted from the included studies for the qualitative synthesis. Studies were not assessed for quality as our research question was which mesenchymal and functional markers are most commonly used in the vascular research field and quality of the studies was therefore irrelevant.
Data S3. Movat Pentachrome Protocol.

**Working solutions:**

(A) 1% Alcian Blue Solution: 1 g Alcian Blue 8 GX (Merck, Burlington, US), 100 ml distilled water, 1 ml Glacial Acetic Acid (Sigma Aldrich, Saint Louis, US)

(B) Alkaline Alcohol solution: 10 ml Ammonium Hydroxide (Merck, Burlington, US), 90 ml Ethanol 100%.

(C) Elastic Hematoxylin Solution: 25 ml 10% Alcoholic Hematoxylin (J), 25 ml Ethanol 100%, 25 ml 10% Ferric Chloride (D), 25 ml Verhoeff’s Iodine Solution (K).

(D) 10% Ferric Chloride Solution: 10 g Ferric Chloride (Sigma Aldrich, Saint Louis, US), 100 ml distilled water

(E) 5% Sodium Thiosulfate Solution: 5g Sodium Thiosulfate (Sigma Aldrich, Saint Louis, US), 100 ml distilled water

(F) Biebrich Scarlet/Acid Fuchsin solution: pre-made from ScyTek Laboratories (Logan, United States).

(G) 1% Acetic Acid Solution: 1 ml Glacial Acetic Acid, 99 ml distilled water

(H) 5% Aqueous Phosphotungstic Acid solution: 5 g Phosphotungstic Acid (Sigma Aldrich, Saint Louis, US), 100 ml distilled water

(I) 4% Alcoholic Saffron Solution: 4 g Saffron (Safranor Safran du Gâtinais, Échilleuses, France), 100 ml Ethanol 100%.
10% Alcoholic Hematoxylin Solution: 10 g Hematoxylin (Merck, Burlington, US), 100 ml Ethanol 100%

Verhoeff’s Iodine Solution: 2 g Iodine Crystals (Sigma Aldrich, Saint Louis, US), 4 g Potassium Iodide (Sigma Aldrich, Saint Louis, US), 100 ml distilled water

Protocol:

1. Deparaffinization and rehydration of slides. 2. Rinse slides in distilled water. 3. Stain in 2 changes with (A), both times for 15-25 minutes. 4. Rinse slides in running warm to hot water until clear. 5. Place slides in (B) for 30 minutes, then rinse in running tap water. 6. Stain in (C) for 20 minutes. 7. Rinse in running warm tap water. 8. Differentiate in 2% aqueous (D) for 5 seconds-2 minutes. 9. Place slides in (E) for about 1 minute. 10. Wash in running tap water and rinse in distilled water. 11. Stain in (F) for 1-1.5 minutes. 12. Rinse in distilled water. 13. Rinse in (G) for 7-12 seconds. 14. Place slides in (H) for 7-12 minutes. 15. Rinse in distilled water. 16. Rinse in (G) for 8-10 seconds. 17. Place in 2 changes of Ethanol 100%. 18. Stain in (I) for 1.5 minute and quickly rinse in Ethanol 100%. 19. Dehydration of slides.
Table S1. Excluded full-texts in Systematic Search.

| Number | Publication                                                                 | Reason                                      |
|--------|------------------------------------------------------------------------------|---------------------------------------------|
| 1      | Owens GK. Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. *Novartis Found Symp.* 2007;283:174-91. | Conference proceeding.                      |
| 2      | Bentzon JF, Majesky MW. Lineage tracking of origin and fate of smooth muscle cells in atherosclerosis. *Cardiovasc Res.* 2018;114(4):492-500. | No marker proteins for differentiation described. |
| 3      | Maegdefessel L, Rayner KJ, Leeper NJ. MicroRNA regulation of vascular smooth muscle function and phenotype: early career committee contribution. *Arterioscler Thromb Vasc Biol.* 2015;35(1):2-6. | No marker proteins for differentiation described. |
| 4      | Matchkov VV, Kudryavtseva O, Aalkjaer C. Intracellular Ca²⁺ signalling and phenotype of vascular smooth muscle cells. *Basic Clin Pharmacol Toxicol.* 2012;110(1):42-8. | No marker proteins for differentiation described. |
| 5      | Song Z, Li G. Role of specific microRNAs in regulation of vascular smooth muscle cell differentiation and the response to injury. *J Cardiovasc Transl Res.* 2010;3(3):246-50. | No marker proteins for differentiation described. |
| 6      | Erlinge D. Extracellular ATP: a central player in the regulation of vascular smooth muscle phenotype. Focus on "Dual role of PKA in phenotype modulation of vascular smooth muscle cells by extracellular ATP". *Am J Physiol Cell Physiol.* 2004;287(2):C260-2. | No marker proteins for differentiation described. |
| 7      | Bochaton-Piallat ML, Bäck M. Novel concepts for the role of smooth muscle cells in vascular disease: towards a new smooth muscle cell classification. *Cardiovasc Res.* 2018;114(4):477-480. | No marker proteins for differentiation described. |
| 8      | Shi N, Mei X, Chen SY. Smooth Muscle Cells in Vascular Remodeling. *Arterioscler, Thromb. Vasc. Biol.* 2019;39(12):e247-e252. | No marker proteins for differentiation described. |
| 9      | Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. *Nat Rev Cardiol.* 2019;16(12):727-744. | No full-text available in Leiden University Medical Library collection. |
| 10     | Kannenberg F, Gorzelniak K, Jager K, Fobker M, Rust S, Repa J, Roth M, Bjorkhem I, Walter M. Characterization of cholesterol homeostasis in telomerase immortalized tangier disease fibroblasts reveals marked phenotype variability. *J. Biol. Chem.* 2013;288(52):36936-36947. | No marker proteins for differentiation described. |
| Protein marker | Reason for exclusion |
|----------------|----------------------|
| DDR215,310     | <3 references         |
| NGS97          | Primarily pericyte marker |
| Anti-reticular fibroblast marker (RFM)97 | <3 references |
| MHC class I302 | <3 references         |
| CD4302         | <3 references         |
| **Acting binding proteins** |                     |
| Cofilin16      | <3 references         |
| Profilin16     | <3 references         |
| Talin176       | <3 references         |
| MYPT-116       | <3 references         |
| **Cytoskeleton proteins** |               |
| Tubulin98      | <3 references         |
| Metavinculin40,42,111 | Vinculin selected |
| Leiomodin-1111 | <3 references         |
| Integrins (A1,A7,B1)211,294 | <3 references |
| Myocardin111,222,294 | Master regulator of SMC differentiation. Panel of contractile markers included yet. |
| N-Cadherin/T-Cadherin96,294 | <3 references |
| Calmodulin111,214,249 | Telokin selected |
| LPP38          | <3 references         |
| Myosin light chains (LC17a en LC17b)39 | <3 references |
| Cysteine- and glycine-rich protein 191 | <3 references |
| 1E12226        | <3 references         |
| Phospholamban228,300 | Expressed specifically in cardiac muscle. |
| Aquaporin-1228,300 | <3 references |
| Osteoglycin228 | <3 references         |
| Ubiquitin228   | <3 references         |
| APEG-1294      | <3 references         |
| CRP-2294       | <3 references         |
| MAS5300        | <3 references         |
Table S3. Excluded full-texts in synthetic/inflammatory marker search.

| Number | Publication                                                                 | Reason                                                                 |
|--------|----------------------------------------------------------------------------|------------------------------------------------------------------------|
| 1      | Owens GK. Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. *Novartis Found Symp*. 2007;283:174-91. | Conference proceeding.                                                 |
| 2      | Bentzon JF, Majesky MW. Lineage tracking of origin and fate of smooth muscle cells in atherosclerosis. *Cardiovasc Res*. 2018;114(4):492-500. | No marker proteins for differentiation described.                       |
| 3      | Maegdefessel L, Rayner KJ, Leeper NJ. MicroRNA regulation of vascular smooth muscle function and phenotype: early career committee contribution. *Arterioscler Thromb Vasc Biol*. 2015 Jan;35(1):2-6. | No marker proteins for differentiation described.                       |
| 4      | Matchkov VV, Kudryavtseva O, Aalkjaer C. Intracellular Ca²⁺ signalling and phenotype of vascular smooth muscle cells. *Basic Clin Pharmacol Toxicol*. 2012;110(1):42-8. | No marker proteins for differentiation described.                       |
| 5      | Song Z, Li G. Role of specific microRNAs in regulation of vascular smooth muscle cell differentiation and the response to injury. *J Cardiovasc Transl Res*. 2010;3(3):246-50. | No marker proteins for differentiation described.                       |
| 6      | Erlinge D. Extracellular ATP: a central player in the regulation of vascular smooth muscle phenotype. Focus on “Dual role of PKA in phenotype modulation of vascular smooth muscle cells by extracellular ATP”. *Am J Physiol Cell Physiol*. 2004;287(2):C260-2. | No marker proteins for differentiation described.                       |
| 7      | Bochaton-Piallat ML, Bäck M. Novel concepts for the role of smooth muscle cells in vascular disease: towards a new smooth muscle cell classification. *Cardiovasc Res*. 2018;114(4):477-480. | No marker proteins for differentiation described.                       |
| 8      | Shi N., Mei X., Chen S.-Y. Smooth Muscle Cells in Vascular Remodeling. *Arterioscler. Thromb. Vasc. Biol*. 2019;39(12):e247-e252. | No marker proteins for differentiation described.                       |
| 9      | Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. *Nat Rev Cardiol*. 2019;16(12):727-744. | No full-text available in Leiden University Medical Library collection. |
| 10     | Reddy MA, Villeneuve LM, Wang M, Lanting L, Natarajan R. Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. *Circ Res*. 2008;103(6):615-23. Retraction in: *Circ Res*. 2009;105(6):e9. | Retracted publication.                                                |
| 11     | Ramos KS, Weber TJ, Liu G. Altered protein secretion and extracellular matrix deposition is associated with the proliferative phenotype induced by allylamine in aortic smooth muscle cells. *Biochem J*. 1993;289. | No protein markers for differentiation or proliferative/synthetic features described. |
| 12     | 5. Stengel D, O’Neil C, Brochériou I, Karabina SA, Durand H, Caplice NM, Pickering JG, Ninio E. PAF-receptor is preferentially expressed in a distinct synthetic phenotype of smooth muscle cells cloned from human internal thoracic artery: functional implications in cell migration. *Biochem Biophys Res Commun*. 2006;346(3):693-9. | No protein markers for differentiation or proliferative/synthetic features described. |
| 13     | Liu L, Abramowitz J, Askari A, Allen JC. Role of caveolae in ouabain-induced proliferation of cultured vascular smooth muscle cells of the synthetic phenotype. *Am J Physiol Heart Circ Physiol*. 2004;287(5):H2173-82. | No protein markers for differentiation or proliferative/synthetic features described. |
| 14     | Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG, Beavo JA. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human | No protein markers for differentiation or proliferative/ |
| No. | Reference                                                                                                | Notes                                                                 |
|-----|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| 15  | Wang Y, Lindstedt KA, Kovanen PT. Phagocytosis of mast cell granule remnant-bound LDL by smooth muscle cells of synthetic phenotype: a scavenger receptor-mediated process that effectively stimulates cytoplasmic cholesteryl ester synthesis. *J Lipid Res.* 1996;37(10):2155-66. | No protein markers for differentiation or proliferative/synthetic features described. |
| 16  | Kannenberg F, Gorzelniak K, Jager K, Fobker M, Rust S, Repa J, Roth M, Bjorkhem I, Walter M. Characterization of cholesterol homeostasis in telomerase immortalized tangier disease fibroblasts reveals marked phenotype variability. *J. Biol. Chem.* 2013;288(52):36936-36947 | No marker proteins for differentiation described. |
Table S4. Excluded synthetic IHC markers.

| Marker                                                                 | Reason for exclusion                                                                 |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| (pro-)Collagen II, III, VIII<sup>40,208,268</sup>                     | Among all the collagen subtypes, type I collagen is considered to be most abundant in vascular fibrous pathology. |
| Collagenase IV<sup>294</sup>                                          | <3 references                                                                        |
| Heat shock protein 47 (Hsp47)<sup>195</sup>                           | <3 references                                                                        |
| **ECM components**                                                    |                                                                                      |
| Chondroitin sulfate<sup>98</sup>                                      | <3 references                                                                        |
| Vitronectin<sup>40</sup>                                              | <3 references                                                                        |
| Tenascin<sup>232</sup>                                                | <3 references                                                                        |
| Tropoelastin<sup>232</sup>                                            | <3 references                                                                        |
| Fibrillin<sup>233</sup>                                               | <3 references                                                                        |
| Osteoglycin<sup>235</sup>                                             | <3 references                                                                        |
| Syndecan-1/4<sup>104,294</sup>                                        | <3 references                                                                        |
| Versican<sup>20</sup>                                                 | <3 references                                                                        |
| Aortic-carboxypeptidase-like protein (ALCP)<sup>42,91</sup>           | <3 references                                                                        |
| Matrix Gla Protein (MGP)<sup>232,235,317</sup>                       | Predominantly extracellular protein                                                   |
| TGN46<sup>278</sup>                                                   | <3 references                                                                        |
| **Intermediate filaments**                                            |                                                                                      |
| GFAP<sup>278</sup>                                                    | <3 references                                                                        |
| Cytokeratin 8 and 18<sup>111,232</sup>                                | <3 references                                                                        |
| Cyclinfilin A<sup>281</sup>                                           | <3 references                                                                        |
| Zona occludens 2- protein<sup>111</sup>                              | <3 references                                                                        |
| Cingulin<sup>111</sup>                                                | <3 references                                                                        |
| uPa<sup>111</sup>                                                     | <3 references                                                                        |
| tPA<sup>111</sup>                                                     | <3 references                                                                        |
| Connexin 43<sup>104,194</sup>                                         | <3 references                                                                        |
| IGF-BP2<sup>102</sup>                                                | <3 references                                                                        |
| TSP-1<sup>140</sup>                                                   | <3 references                                                                        |
| Cytochrome P-450IA<sup>232</sup>                                     | <3 references                                                                        |
| Osteoprotegerin<sup>241</sup>                                        | <3 references                                                                        |
| SMPD3<sup>105</sup>                                                   | <3 references                                                                        |
| Sortilin-1<sup>105</sup>                                             | <3 references                                                                        |
Table S5. Excluded pro-inflammatory IHC markers.

| Marker         | Reason for exclusion                                           |
|----------------|----------------------------------------------------------------|
| IL-1α<sup>259,263</sup> | <3 references                                                   |
| IL-1β<sup>106,112,162</sup> | Not detectable at protein level<sup>294</sup>                   |
| TNF-α<sup>106,112,162</sup> | Very low expression at protein level<sup>294</sup>              |
| MCSF<sup>109</sup>     | <3 references                                                   |
| TGF-β<sup>177</sup>   | <3 references                                                   |
| Cell activation markers (ICAM-1, VCAM-1, E-selectin, MMP-2, MMP-3, MMP-7, MMP-9)<sup>29,106,112,177,203,260,318</sup> | NF-κB selected as central regulator                             |
| CCR2<sup>19</sup>     | <3 references                                                   |
| MHCII<sup>14</sup>    | <3 references                                                   |
| CXCL1<sup>107,239</sup> | <3 references                                                   |

162-326
Figure S1. Defining the regions of interest within atherosclerotic lesions for semi-quantitative scoring system.

**Abbreviations:** I. Intima M1. Inner media zone M2. Middle media zone M3. Outer media zone Ad. Adventitia VVven. Venule-like vasa vasora VVart. Arteriole-like vasa vasora.
Figure S2. Rabbit IgG in concentrations higher than 1 µm/mL produce significant background.

Overview of rabbit isotype controls in several concentrations (on early fibroatheroma (EFA); 2,5x and 26x magnification). Non-specific binding of rabbit IgG is significantly increased in rabbit IgG concentrations of 1 µg/mL or higher. This phenomenon was not observed in mouse IgG or mouse sera.
Figure S3. Disqualification of Thy-1/CD90 and FSP-1/S100A4 as universal mesenchymal lineage markers.

Fig S3.1. A. The majority of spindle shaped cells in the media of AIT are triple positive for Vimentin$^+$ (in green; AF488; FITC-channel), FSP-1$^+$ (in red; AF546; TRITC-channel) and αSMA$^+$ (in magenta; AF647; Cy5-channel). The inserts show single channel signals for αSMA$^+$ (B) and Vimentin$^+$ (C). Insert (D) shows the presence of αSMA$^+/$/Vimentin$^+/$/FSP-1$^-$ double positive subpopulation.
The majority of spindle shaped cells in the media of AIT are triple positive for Vimentin$^+$ (in green; AF488; FITC-channel), CD90$^+$ (in red; AF546; TRITC-channel) and αSMA$^+$ (in magenta; AF647; Cy5-channel). The inserts show single channel signals for Vimentin$^+$ (C) and αSMA$^+$ (D).

Insert (B) shows the presence of αSMA$^+$/Vimentin$^+$/CD90$^-$ double positive subpopulation.
Figure S4. Challenging Vimentin as an all-inclusive panmesenchymal marker.

Figure S4.1: A. Adaptive Intimal Thickening (AIT) section double IHC stained for FAP (in red) and Vimentin (in blue). In AIT, FAP and Vimentin show almost complete (B/C; in purple).
Figure S4.2. A. Late Fibroatheroma (LFA) section double IHC stained for FAP (in red) and Vimentin (in blue). During atherogenic progression, although FAP expression remained stable in the medial zones (F), FAP expression is unstable in the cap region, shown by spindle-shaped single FAP+ cells (E; arrows, in red), challenging Vimentin as an all-inclusive panmesenchymal marker.
Figure S5. Double Vimentin+/$\alpha$SMA+ cells in the cap of progressive atherosclerotic lesions (LFA and TCFA) and stabilized atherosclerotic lesions (HR).

Figure S5.1: A. Movat Pentachrome staining of LFA (Late Fibroatheroma).

Legend: red, smooth muscle cells/fibrin; violet: leukocytes; black: elastin; blue: proteoglycans/mucins; yellow: collagen. Various shades of green reflect colocalization of collagen (yellow) and proteoglycans (blue).

B. Insert of the cap double IHC stained for Vimentin (in blue) and $\alpha$SMA (in red), showing that the cap is mesenchymal cell (Vimentin+) rich. Approximately 80% of the Vimentin+ cells were double Vimentin+/$\alpha$SMA+ (arrow in B, in purple; star indicates a single Vimentin+/$\alpha$SMA- cell).
**Figure S5.2:** C. Movat Pentachrome staining of TCFA (Thin cap fibroatheroma). For legend see Figure S5.1.

D. Insert of the cap double IHC stained for Vimentin (in blue) and αSMA (in red). Transition from a LFA to a TCFA was associated with a clear decrease in cell density. Approximately 80% of the Vimentin+ cells were double Vimentin+/αSMA+ (arrow in D, in purple; star indicates a single Vimentin+/αSMA- cell).
**Figure S5.3:** E. Movat Pentachrome staining of HR (Thin cap fibroatheroma). For legend see Figure S5.1.

F. Within the cell-rich/proteoglycan-rich luminal granulation tissue that is associated with healing of a ruptured atherosclerotic lesions (HR), approximately 80% of the Vimentin⁺ cells (in blue) were double Vimentin⁺/αSMA⁺ (arrow in D, in purple; star indicates a single Vimentin⁺/αSMA⁻ cell).
Figure S6. Vimentin, Thy-1/CD90, S100A4/FSP-1 and FAP are limited in mesenchymal lineage specificity: expression in monocytic cells.

Figure S6.1: A. Triple IF staining of Vimentin (Vim), clone 1A4, (in green; AF488; FITC-channel), CD45 (in red; Vulcan Red; TRITC-channel) and CD68 (in magenta; AF647; Cy5-channel) in the adventitia. Nuclei are DAPI-stained (blue). Arterial elastic laminae in the medial layer are occasionally visible in greenblue due to auto-fluorescence. The four top inserts show the single channel information for Dapi, Vimentin, CD45 and CD68 (from left to right). Inserts on the down right show overlay information for (B) CD45+/Vimentin+ cells, respectively of which a part is CD68+/Vimentin+/CD45+(C).
**Figure S6.2:** A. Triple IF staining of Vimentin (Vim), clone VI-10, (in green; AF488; FITC-channel), CD45 (in red; Vulcan Red; TRITC-channel) and CD68 (in magenta; AF647; Cy5-channel) in the adventitia. Nuclei are DAPI-stained (blue). Arterial elastic laminae in the medial layer are occasionally visible in greenblue due to auto-fluorescence. The four top inserts show the single channel information for Dapi, Vimentin, CD45 and CD68 (from left to right). Inserts on the down right show overlay information for (B) CD45⁺/Vimentin⁺ cells, respectively of which a part is CD68⁺/Vimentin⁺/CD45⁻ (C).
FigureS6.3: A. Triple IF staining of FSP-1 (in green; AF647; Cy5-channel), CD45 (in red; Vulcan Red; TRITC-channel) and CD68 (in magenta; AF488; FITC-channel) in the adventitia. Nuclei are DAPI-stained (blue). Arterial elastic laminae in the medial layer are occasionally visible in greenblue due to auto-fluorescence. The four top inserts show the single channel information for Dapi, FSP-1, CD45 and CD68 (from left to right). Inserts on the down right show overlay information for (B) CD45+/FSP-1+ cells, respectively of which a part is CD68+/FSP-1+/CD45+(C).
Figure S6.4: A. Triple IF staining of CD90 (in green; AF488; FITC-channel), CD45 (in red; Vulcan Red; TRITC-channel) and CD68 (in magenta; AF647; Cy5-channel) in the adventitia. Nuclei are DAPI-stained (blue). Arterial elastic laminae in the medial layer are occasionally visible in greenblue due to auto-fluorescence. The four top inserts show the single channel information for Dapi, CD90, CD45 and CD68 (from left to right). Inserts on the down right show overlay information for (B) CD45+/CD90+ cells, respectively of which a part is CD68+/CD90+/CD45+(C).
Figure S6.5: A. Triple IF staining of FAP (in green; AF488; FITC-channel), CD45 (in red; Vulcan Red; TRITC-channel) and CD68 (in magenta; AF647; Cy5-channel) in the adventitia. Nuclei are DAPI-stained (blue). Arterial elastic laminae in the medial layer are occasionally visible in greenblue due to auto-fluorescence. (B) The four top inserts show the single channel information for Dapi, FAP, CD45 and CD68 (from left to right). Inserts on the down right show overlay information for (B) CD45+/FAP+ cells, respectively of which a part is CD68+/FAP+/CD45+(C).
**Figure S7.** Limited mesenchymal lineage specificity of Vimentin: expression in endothelial cells. Thy-1/CD90, S100A4/FSP-1 and FAP are not expressed in endothelial cells.

**Figure S7.1:** A. Movat Pentachrome staining of EFA (Early Fibroatheroma). Legend: *red*, smooth muscle cells/fibrin; *violet*, leukocytes; *black*, elastin; *blue*, proteoglycans/mucins; *yellow*, collagen. Various shades of green reflect colocalization of collagen (*yellow*) and proteoglycans (*blue*). B. Close up of intact endothelium in the arterial wall and of endothelial cells in a vasum vasorum (C).
Figure S7.2: D. Double IF staining of Vimentin (cytoplasm staining, in green; AF488; FITC-channel) and CD31 (plasma membrane and cell junction staining, in red; Vulcan Red; TRITC-channel) of a consecutive section of the EFA shown in A. Nuclei are DAPI-stained (in blue).

The inserts on the left shown single channel information for Vimentin (E1/F1) and CD31 (E2/F2). Vimentin and CD31 colocalize in the arterial intima (E3) and in endothelial cells in the vasa vasora (F3).
Figure S7.3: G1. Close up of single positive CD31+ (in green; AF488; FITC-channel; plasma membrane and cell junction staining)/CD90− endothelial cells in the arterial wall. G2. Close up of CD90+/CD31− cells (in red; Vulcan Red; TRITC-channel; plasma membrane staining) that are in close proximity of CD31+ endothelial cells (in green; AF488; FITC-channel; plasma membrane and cell junction staining) in vasa vasora. Nuclei are DAPI-stained (in blue).
Figure S7.4: H1. Close up of FSP-1+ cells (in red; Vulcan Red; TRITC-channel, nucleus and cytoplasm staining) are in close proximity of single CD31+ endothelial cells (in green; AF488; FITC-channel; plasma membrane and cell junction staining) in vasa vasora. Nuclei are DAPI-stained (in blue).
Figure S7.5: H1. Close up of single FAP$^+$ cells (in red; Vulcan Red; TRITC-channel, nucleus and cytoplasm staining) that are in close proximity of CD31$^+$ endothelial cells (in green; AF488; FITC-channel; plasma membrane and cell junction staining) in vasa vasora. Nuclei are DAPI-stained (in blue).
Figure S8. Role for EndoMT/ stem cells in vascular pathology.

Figure S8.1: A. Double IHC staining of CD31 (in blue) and Vimentin (in red) on LFA. The inserts (B/C) show solitary double Vimentin+/CD31+ cells in the vicinity of the vasa vasora (in purple; arrows).
Figure S8.2: D. Double IHC staining of CD34 (in blue) and Vimentin (in red) on LFA. The inserts (E/F) show solitary double Vimentin⁺/CD34⁺ cells in the vicinity of the vasa vasora (in purple; arrows).
Figure S9. Fibrocytes in luminal vascular repair sites.

Figure S9.1: A. Healed Rupture (HR) stained by Movat pentachrome. Plaque consolidation (wound healing process) is characterized by a spindle-shaped mesenchymal-rich (B; nuclei in red) and proteoglycan-rich matrix (B; green-blue) cap covering the fibrotic remnants of the former cap (A; yellow region). C. Confocal images of spindle-shaped double Vimentin+ (in green; AF488)/ CD45+ (in red; AF647) in the proteoglycan-rich granulation tissue. C1. Shows single channel information for Vimentin and C2 shows single channel information for CD45.
Figure S9.2: D. Late Fibroatheroma (LFA) double IHC stained for Vimentin (in red) and CD45 (in blue). E. In the cap of LFA, both spindle shaped double Vimentin+/CD45+ (arrow) cells and round-shaped double Vimentin+/CD45+ (stars) are present.
Figure S9.3: F. Fibrocalcific Plaque (FCP) double IHC stained for Vimentin (in red) and CD45 (in blue). E. In the neo-intima of FCP, both spindle shaped double Vimentin⁺/CD45⁺ (arrow) cells and round-shaped double Vimentin⁺/CD45⁺ (stars) are present.
Figure S10. Subset of elongated Smemb+ are synthetic.

Figure S10: A. Late Fibroatheroma (LFA) section double IHC stained for Smemb (in red) and P4HB (in blue). Most Smemb+ elongated cells in the cap and shoulder region were found to also express the synthetic marker P4HB, but single Smemb+ elongated cells were also present in these regions (B; arrows).
**Figure S11. Spatial distribution of h1-Calponin in progressive atherosclerosis.**

**Figure S11.1:** A. Adaptive Intimal Thickening (AIT) section double IHC stained for αSMA (in red) and h1-Calponin (in blue). In AIT, they show complete colocalization (B; in purple), except from the vasa vasora which are often single αSMA- (A; in red).
Figure S11.2: A. Late Fibroatheroma (LFA) section double IHC stained for αSMA (in red) and h1-Calponin (in blue). In LFA, there is a dissociation of the staining pattern for αSMA and h1-Calponin in the cap/shoulder region, reflected by single h1-Calponin/αSMA+ cells (in red).
Figure S12. Tropomyosin, Telokin and Paxillin are not contractile cell specific.

Figure S12.1: A. Triple staining of Tropomyosin (in magenta; AF647; Cy5-channel), Vimentin (in green; AF488; FITC-channel) and CD45 (in red; Vulcan Red; TRITC-channel) in the adventitia. The three left inserts show the single channel information for Tropomyosin (B), Vimentin (C) and CD45 (D), counterstained by Dapi (in blue). The vast majority of Tropomyosin+ cells were triple positive for Tropomyosin+/Vimentin+/CD45+. 
Figure S12.2: F. Triple staining of Telokin (in magenta; AF647; Cy5-channel), Vimentin (in green; AF488; FITC-channel) and CD45 (in red; Vulcan Red; TRITC-channel) in the adventitia. The three left inserts show the single channel information for Telokin (G), Vimentin (H) and CD45 (I), counterstained by Dapi (in blue). The vast majority of Telokin+ cells were triple positive for Telokin+/Vimentin+/CD45+.
Fig S12.3: A. Triple staining of Paxillin (in magenta; AF647; Cy5-channel), Vimentin (in green; AF488; FITC-channel) and CD45 (in red; Vulcan Red; TRITC-channel) in the adventitia. The three left inserts show the single channel information for Paxillin (B), Vimentin (C) and CD45 (D), counterstained by Dapi (in blue). Although the vast majority of Paxillin+ cells in the adventitia were triple positive for Paxillin+/Vimentin+/CD45+, single Vimentin+ cells were also present (A).
Figure S13. αSMA challenged as all-inclusive contractile marker.

Figure S13.1: A. Adaptive Intimal Thickening (AIT) section double IHC stained for αSMA (in red) and Tropomyosin (in blue). In AIT, single αSMA+ cells (arrows in B) are present in the intima, as well as in the outer media. In the inner and medial media, all elongated cells are double αSMA+/Tropomyosin+ (in purple), but Tropomyosin is expressed in varying degrees (C. arrows: αSMA<sup>high</sup>/Tropomyosin<sup>low</sup>).
Figure S13.2: A. Late Fibroatheroma (LFA) section double IHC stained for αSMA (red) and Tropomyosin (blue). While in the media Tropomyosin and αSMA show complete overlap (C), in the cap and shoulder regions in LFA both single αSMA⁺ cells and single Tropomyosin⁺ cells are present (B; arrows).
Figure S14. Excluded synthetic and pro-inflammatory IHC markers.

Figure S14.1: IHC Stainings of Collagen-I (Rabbit IgG), MBS502155, MyBioSource. In FCP tissue, significant non-specific staining was present, regardless of protein block usage and use of either a heat retrieval (A. Tris-EDTA, dilution 1:400) or an enzyme retrieval (C. Pepsin, dilution 1:400), similarly for AAA tissue (E. Tris-EDTA, dilution 1:400; G. Pepsin, dilution 1:400).
Figure S14.2: IHC Stainings of Collagen-I (Goat IgG), C7510-17K, USBIO. In AAA tissue, and even more outspoken in FCP tissue (E. Citrate, dilution 1:250), significant non-specific staining was present, regardless of protein block usage and use of either a heat retrieval (A. Citrate, dilution 1:250) or an enzyme retrieval (C. Pepsin, dilution 1:250).
Figure S14.3: IHC Stainings of Pro-collagen-I (Rat IgG1), clone MAB1912, Millipore. In EFA tissue, regardless of antigen heat retrieval pH (A. Tris-EDTA, dilution 1:500; B. Citrate, dilution 1:500), there was little to no signal. However, in positive controls (C. AAA tissue, Tris-EDTA, dilution 1:500), a lot of non-specific staining was present, especially in lymphocyte infiltrates.
Figure S14.4: IHC Stainings of Pro-collagen-I (Mouse IgG1), clone PC8-7, Abnova. In EFA tissue, regardless of antigen heat retrieval pH (A. no retrieval, dilution 1:300; C. Tris-EDTA, dilution 1:300; E. Citrate, dilution 1:300), no protein expression was detected, confirmed by absence of staining in positive controls (H. AAA, no retrieval, dilution 1:300; I. AAA, Tris-EDTA, dilution 1:300). In contrast, in higher concentrations (G. dilution 1:100, EFA, no retrieval) there was significant background staining.
Figure S14.5: IHC Staining of Osteopontin (Goat IgG), AF1433, R&D Systems.  

A. (PIT (Pathological Intimal Thickening) tissue, Tris-EDTA, dilution 1:400).  

B. As Osteopontin is an ECM-protein (arrows), it is less convenient for cell phenotyping.
Figure S14.6: IHC Staining of Fibronectin (Mouse IgG1), clone FBN11, Thermofisher. A (LFA tissue, no retrieval, dilution 1:900). B. As Fibronectin is an ECM-protein (arrows), it is less convenient for cell phenotyping.
Figure S14.7: IHC staining of Laminin (Rabbit IgG), ab11575, Abcam. A. (Thin-cap Fibroatheroma tissue (advanced atherosclerosis), no retrieval, dilution 1:200). B. As Laminin is an ECM-protein (arrows), it is less convenient for cell phenotyping.
Figure S14.8: IHC staining of CRBP-1 (Rabbit IgG), ab11575, Abcam. In EFA (Early Fibroatheroma; advanced atherosclerosis) and AAA, no CRBP-1 signal was present, regardless of high primary antibody concentration and various antigen retrieval (A. EFA, Tris-EDTA, 1:30; C. EFA, Citrate, 1:30; E. EFA, Pepsin, 1:30; G. AAA, Tris-EDTA, 1:30; I. AAA, Citrate, 1:30; K. AAA, Pepsin, 1:30).
Although PDGFR-α is expressed on the cell membrane, nuclear staining was observed (arrows in B (Citrate, dilution 1:400) and D (Tris-EDTA, dilution 1:400)). A small number of studies\textsuperscript{326,327} has reported nuclear localization of the PDGFR-α, but those observations are based on IHC/IF, which makes it questionable whether it is really localized in the nucleus or whether it is background staining.
Figure S14.10: IHC Stainings of Phospho-NFκB p65 (Mouse IgG1), clone MCFA30, ThermoFisher. Although AAA is typically highly infiltrated by immune cells, there was weak staining of NFκB, regardless several antigen retrievals (A. Citrate, dilution 1:100; C. Tris-EDTA, dilution 1:100; E. Pepsin, dilution 1:100). In higher concentrations, more background staining was observed (I. Tris-EDTA, dilution 1:50). As NFκB is expressed intracellularly, the contribution of 0.1% Triton X-100 in PBS was also tested, although most nuclei are dissected in the 4 µ-sections (G. Citrate, Triton X-100, dilution 1:100; K. Pepsin, Triton X-100, dilution 1:100). However, more background (cytoplasmatic) staining was present if Triton X-100 was applied.
Figure S14.11: IHC Stainings of Phospho-NFκB 105 (Mouse IgG1), 178F3, Cell Signaling Technology.

Although AAA is typically highly infiltrated by immune cells, there was weak staining of NFκB, regardless several antigen retrievals (A. Tris-EDTA, dilution 1:100; C. Citrate, dilution 1:100; E. Pepsin, dilution 1:100). In higher concentrations, more background staining was observed (K. Tris-EDTA, dilution 1:50). As NFκB is expressed intracellularly, the contribution of 0.1% Triton X-100 in PBS was also tested, although most nuclei are dissected in the 4 µ-sections (G. Tris-EDTA, Triton X-100, dilution 1:100; I. Citrate, Triton X-100, dilution 1:100). However, more background (cytoplasmatic) staining was present if Triton X-100 was applied.
Figure S14.12: IHC Stainings of MCP-1 (Mouse IgG2b), 23002, R&D Systems.

Weak to no staining of MCP-1 in infiltrates of AAA tissue, regardless antigen retrieval (A. Tris-EDTA, dilution 1:100; B. Pepsin, dilution 1:100) and high primary antibody concentration (C. Tris-\text{-}vEDTA, dilution 1:50).
**Figure S15. Illustration of inflammatory cells in atherosclerosis.**

**Figure S15.1:** A. Double IHC staining for T-cells (CD4/CD8 co-staining; in *red*) and macrophages (CD68; in *brown*) in AIT reference sample (early atherosclerosis). B. Close up of T-cells (arrows) in the intima and C. close up of macrophages (arrows) in the adventitia.
**Figure S15.2:** D. Double IHC staining for T-cells (CD4/CD8 co-staining; in red) and macrophages (CD68; in brown) in LFA reference sample (progressive atherosclerosis). E. Close up of T-cells (left arrow) and macrophages (right arrow) in cap area. F. Close up of macrophages (left arrow) and T-cells (right arrow) in adventitia.
Figure S15.3: G. Double IHC staining for T-cells (CD4/CD8 co-staining; in red) and macrophages (CD68; in brown) in FCP reference sample (end-stage atherosclerosis). H. Close up of macrophages in the neo-intima. I. Close up of macrophages (left arrow) and T-cells (right arrow) in the adventitia.